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ABSTRACT 
 
The delivery of therapeutic agents for the hard-to-treat tumors is restricted by 
inefficacy and non-selectivity of systemically administered drug delivery 
vectors. Therefore, novel approaches aimed at increasing the specificity and in 
turn the treatment efficacies of therapeutic drugs are required. During recent 
years, drug delivery systems, which comprise both targeting and anticancer 
chemotherapy strategies, have received much attention. In this regard, the 
application of cell-penetrating peptides appears to be a very promising strategy 
for targeted drug delivery. Cell-penetrating peptide-based vehicles have been 
developed for the delivery of different payloads into the cells in culture and in 
animals. However, similar issues as for any other drug delivery system: cyto-
toxicity and the tendency to induce innate immune response may limit their use. 
The current thesis is focused on the characterization of immunogenic and 
cytotoxic activities of cell-penetrating peptides PepFects, on the cytotoxic and 
apoptotic activities of newly designed cell-penetrating p53 analogues and on the 
development of a peptide-based glioma-targeted drug delivery vector. 
In Paper I, the cytotoxic and immunogenic activities of PepFect peptides and 
PepFect/nucleic acid complexes were analyzed in vitro and in vivo. The current 
study confirmed that PepFect peptides possess promising potential in nucleic 
acid delivery without evidence of undesired cytotoxicity and inflammation at 
the concentrations of 10 μM and 5 μM, respectively in vitro and at a dose of  
5 mg/kg in vivo. 
In Paper II, we generated short p53-derived cell-penetrating protein 
analogues and analyzed their internalization efficacy, cytotoxic and apoptotic 
activities in the neuroblastoma and breast cancer cell lines. Even though the 
effect was observed under serum-free conditions, the novel protein analogues 
demonstrated selective apoptotic activity in the p53-non-active breast cancer 
cell line suggesting promising perspectives for a future anticancer strategy. 
In Paper III, a novel tumor-selective peptide-based drug delivery platform 
gHoPe2 has been developed demonstrating potential application of CPP-s for 
tumor-targeted delivery.  
In Paper IV, we showed that N-terminal modification of non-amphipathic 
(RxR)4  with stearic acid moiety resulted in efficient peptide vector for nucleic 
acids delivery in non-toxic manner. 
In conclusion, the current work provides evidence for the development of 
apoptotic protein-derived cell-penetrating peptides and tumor-targeted cell-
penetrating peptide-based drug delivery vector with reduced toxicity and 
immunogenicity.  
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INTRODUCTION 
 
Efficient intracellular internalization of therapeutic agents is often necessary to 
gain the desired therapeutic effect. The hydrophobic interior of the lipid bilayer 
makes the cellular membrane impermeable to molecules with high molecular 
weight such as nucleic acids (pDNA, siRNA, oligonucleotides), proteins, etc., 
serving as a protective wall between the cytoplasm and extracellular environ-
ment. Therefore, the use of these bioactive compounds for therapeutic appli-
cations has been restricted. The impermeability of the cellular membrane has 
become the major obstacle for current drug research and development.1 Several 
drug delivery techniques have been proposed to promote efficient internali-
zation of the therapeutics inside the cell. For instance, electroporation, encap-
sulation in polymers or liposomes, and viral delivery systems are widely 
utilized. However, several shortcomings including complex manipulation, low 
efficiency, cytotoxicity and undesired immunogenicity can limit their clinical 
application.2, 3 
Cell-penetrating peptides (CPP-s) have proven their ability to deliver various 
drug molecules, DNA, RNA and proteins into cultured cells. CPP-s, also called 
PTD-s (protein transduction domains) are a class of peptides that has drawn 
much attention in the last few decades as non-toxic and non-immunogenic 
vehicles for the systematic delivery of different payloads. Being less than 30 
amino acids in length with net positive charge and/or amphipathic nature these 
peptides are able to deliver a wide range of cargos through cell membrane both 
in vitro and in vivo. CPP-s can be utilized as delivery vectors for peptides, 
proteins, nucleic acids and chemotherapeutics.4, 5 Most CPP-s are able to 
penetrate into the cell regardless to the cell type and proliferative state, which is 
a great advantage especially when delivery to such hard-to-reach tissues like 
brain or the parenchyma is preferred.6 With regards to unspecific internalization 
and high membrane-penetrating activity, potential side effects such as cytotoxi-
city and immunogenicity of CPP-s should be considered. These undesired 
effects can be overcome by addition of the specificity to CPP-based drug deli-
very vectors using novel targeting strategies for instance homing peptide 
sequences determined by in vitro or in vivo phage display methodology.7 
Prediction of short cell-penetrating peptide sequences using a quantitative 
structure-activity relationship algorithm gives an advantage for the generation 
of novel, more efficient therapeutic agents which comprise both cell-penetrating 
and biological activities within the primary sequence.8 
The main aims of this thesis are:  
1) to characterize the immunogenic and cytotoxic activities of the novel 
CPP-s PepFect-s as well as peptide/nucleic acid complexes in vitro and 
in vivo;  
2) to analyze the cytotoxic and pro-apoptotic activities of novel cell-
penetrating p53 analogues, whereof sequences were established using 
structure-activity prediction algorithm;  
3) to develop a peptide-based glioma-targeted drug delivery vector; 
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4) to assess the effect of N-terminal stearyl modification of the CPP-s on 
the nucleic acids delivery in vitro in non-toxic manner. 
The monitoring of newly designed CPP-s for cytotoxicity and immunogenicity 
is essential for the complete understanding of the effects of therapeutic agents in 
vivo.  
The incorporation of a tumor-targeted sequence into the drug delivery vector 
enhances the efficacy of the anticancer drugs improving their biodistribution 
and reducing the toxicity in normal tissues.  
Utilization of the mathematical prediction model allows the creation of 
peptides bearing both cell-penetrating and specific apoptogenic activity, 
demonstrating great possibilities for the identification of various proteomi-
metics, which would represent a new class of therapeutic agents. 
4
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1. LITERATURE OVERVIEW 
 
1.1. Tumor Targeting 
In the past few decades, significant progress has been achieved in understanding 
the molecular principles of malignant transformation and tumorigenesis. 
Insights into the genetic and physiological processes of tumorigenesis and 
tumor progression have resulted in the development of several novel classes of 
chemotherapeutic compounds. Different growth factor receptor and proteasome 
inhibitors and antiangiogenic agents have been shown to selectively interfere 
with tumor cell viability in vitro and in vivo, improving the balance between the 
efficacy and toxicity of systemic anticancer therapy.9, 10 However, the non-
specific biodistribution of intravenously administrated therapeutic agents often 
limit their application. For instance, the majority of routinely used, low mole-
cular anticancer agents are cleared rapidly from systemic circulation by means 
of renal filtration, which prevents them from reaching tumor tissues. The small 
size and relatively high hydrophobicity of the most therapeutic molecules are 
also a reason for their non-specific distribution, resulting in toxicity in many 
different healthy tissues.11 Additionally, several anatomical and physiological 
barriers such as vascular endothelium, the blood brain barrier, cellular and 
nuclear membranes, hepatic degradation, high interstitial fluid pressure and 
drug efflux pumps limit the delivery of intravenously-applied anticancer agents 
to the tumors.12 The majority of tumor-targeted drug delivery systems have been 
developed to overcome these limitations. The principle of tumor-targeted 
delivery is to enhance the antitumor effect by targeting the drug to the tumor 
site, thereby increasing its specific delivery into the malignant tissues (site-
specific delivery), and subsequently by directing the drug away from sites, 
which are particularly sensitive to the toxic effects (site-avoidance delivery), 
reducing the damage of normal tissues.11, 13–17 Based on the mode of drug cargo 
transportation to the tumor site the targeting can be defined as passive targeting 
or active targeting. 
 
 
1.1.1. Passive Targeting 
Passive targeting was shown for the first time in 1986 by Hiroshi Maeda, who 
administered i.v. the albumin-binding Evans Blue dye into the mice bearing 
subcutaneously growing tumors and observed a surprisingly efficient accumu-
lation of the Evans Blue-albumin complex within the tumors.18 This pheno-
menon was further explained by the specific anomalies in the malignant tissues 
that result from the pathophysiology of the tumors. Unlike normal tissues, blood 
vessels of the malignants are characterized by irregular shape and poor 
alignment of the endothelial cells being disorganized with the relatively large 
fenestrations in the range around 100–500 nm in diameter.19, 20 These anato-
mical features make the vasculature of tumor tissue permeable for different 
macromolecules including albumin and even larger nano-sized particles. In 
15 
contrast with smaller molecules that are rapidly cleared from the tumor 
intestitium, the larger molecules when reached the tumors start accumulating 
due to the absence of the lymphatic system.21, 22 This so-called “enhanced 
permeability and retention” (EPR)22, 23 effect has laid the foundation for the 
developing of different tumor-targeted drug delivery systems ranging from 
micro- and macro-particles, to liposomes, to various drug conjugates with 
synthetic polymers, to serum proteins.21, 24 
 
 
1.1.2. Active Targeting 
The study of active targeting received a great impulse in 1975, when Köhler and 
Milstein developed the strategy of monoclonal antibodies.25 Utilization of this 
technique enabled derivation of pure antibodies that bound specifically to the 
targets overexpressed on tumor cells. In contrast to passive targeting that 
exploits the pathophysiologic anomalies of malignant tissues, active targeting is 
based on cellular differences between normal and cancer tissue, focusing on the 
specific molecular interactions with tumor-associated cell receptors or anti-
gens.24 Active targeting relies on the ability of various targeting ligands (anti-
bodies, targeting peptides) to specifically bind to the receptors overexpressed in 
tumors.11, 26, 27 Therefore, active targeting strategy is used to improve tumor cell 
recognition and cellular uptake of drug delivery agents, thereby diminishing 
their accumulation in normal tissues. Targeting ligands such as folate,28 
transferrin29 and galactosamine30 are routinely used for active targeting of 
nanomedicine formulations to tumor cells. Antibodies towards the surface 
proteins have also been used as targeting moieties for drug delivery systems. 
For instance, antibodies targeting CD20, CD25 and CD33 chemokine receptors, 
overexpressed in B-cell lymphoma, T-cell lymphoma and acute myeloid 
leukaemia, respectively, have been successfully used for delivering radio-
nuclides (Zevalin), immunotoxins (Ontak) and antitumour antiobiotics 
(Mylotarg) selectively to tumour cells.11, 12 
 
 
1.2. Drug delivery systems 
The concept of cancer drug delivery implies transporting the anticancer drug to 
the tumor tissue and cells with subsequent release, either intra- or 
extracellularly. Drug delivery systems can be generally classified as micro- and 
macro-particulate drug delivery systems, high-molecular-, and low-molecular-
weight drug conjugates.21, 24 The drugs can be covalently bound to various drug 
carriers for development of low- and high-molecular weight drug conjugates or 
encapsulated in liposomes, nanoparticles, hydrogels or micelles forming micro- 
and macro-molecular drug delivery systems (Table 1).24 
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Table 1. Classification of drug delivery systems24  
 
Micro- and macro-
molecular drug delivery 
systems 
High-molecular weight 
drug conjugates 
Low-molecular weight 
drug conjugates 
 Liposomes 
 Nanoparticles 
 Hydrogels 
 Micelles 
Drug carriers: 
 Antibodies 
 Synthetic polymers 
 Natural polymers 
 Serum proteins 
Drug carriers: 
 Vitamins 
 Homing peptides 
 CPP-s 
 Aptamers 
 Fatty acids 
 Pro-drugs 
 
 
Drug conjugates developed for active targeting include both high- and low-
molecular weight carriers, although high-molecular delivery systems with dia-
meters exceeding 50 nm are preferred.24, 31 These drug delivery systems 
comprise the encapsulation of a drug inside a suitable carrier as well as 
conjugation of the drugs with vitamins,32 lipids,33 peptides,34, 35 aptamers,36 
antibodies,37, 38 synthetic or natural polymers,39–48 liposomes,49, 50 or protein51–53- 
or polymer-based nano- or microparticles.54–56 Similar approaches can also be 
used for the delivery of DNA and RNA molecules.57–63 The covalent coupling 
or the physical encapsulation of the drug inside the carrier enables active or 
passive targeting drug delivery strategies. Low- and high-molecular weight drug 
delivery systems interacting with tumor-associated receptors are internalized 
into the tumor cell via receptor-mediated endocytosis. The drug delivery 
systems using passive targeting strategy are internalized by adsorptive or fluid-
phase endocytosis.64 Endosomes, which form during endocytosis, are either 
transported to certain cell organelles (e.g., the Golgi apparatus), return to the 
cell surface, or form primary and secondary lysosomes. These sorting 
procedures depend on the drug carrier and the kind of endocytosis this drug 
carrier utilizes for internalization.65  
Macromolecular drug delivery systems are more heterogeneous than low-
molecular weight ones, being dispersed in molecular weight, charge distribu-
tions, and a range of drug loading ratios. These drug delivery systems comprise 
drug conjugates with antibodies, synthetic polymers or liposomes, and nano-
particles and microparticles.24, 66, 67 
An ideal drug carrier should combine optimal loading and release properties 
(effective release at the tumor site via enzymatic cleavage or in a pH-dependent 
manner), long-term circulation (sufficient stability in the bloodstream), low 
toxicity, and high affinity for the receptor or antigen without increasing drug 
levels in healthy tissue.68 Although the majority of drug delivery approaches 
have obtained convincing results in tumor-bearing animal models and even 
passed the phase I–III trials, only a few of them have reached market approval, 
for instance liposomes69 (Doxil®, Daunosome®, Myocet®), the albumin taxol 
nanoparticle70 Abraxane®, and the drug–polymer conjugate SMANCS71 (a 
17 
conjugate of poly (styrene-co-maleic acid/anhydride) and the antitumor agent 
neocarzinostatin).24 
 
1.2.1. Cell-penetrating peptides  
Cell-penetrating peptides (CPP-s) are relatively short, up to 30 amino acid-long 
peptides that are capable of crossing the plasma membrane and transport 
various cargo molecules into the cell (Table 2). These properties make them 
attractive drug delivery vectors, especially considering their high cell internali-
zation efficacy and low cytotoxicity.6 In 1988, the cellular uptake of HIV-1 
transcriptional trans-activator protein TAT was demonstrated.72, 73 Later, the 
cell-penetrating activity of penetratin,74 a peptide derived from the antennapedia 
homeodomain protein of Drosophila and TAT75 were described. The greatest 
breakthrough in the CPP field occurred when it was found that the cell-
penetrating properties of some proteins depend on the short protein domains and 
that these protein domains are able not only to translocate through the cellular 
membrane themselves but also are capable of taking cargo with them.  
Another breakthrough occurred when the application of CPP-s in vivo for the 
delivery of PNA, small peptides and large proteins was demonstrated.76, 77 
Thereafter numerous applications of the CPP-s in vivo have been reported 
suggesting that they are one of the most promising approaches for the 
development of non-invasive and non-toxic drug delivery systems.  
It was first suggested that the CPP-s internalize inside the cells using an 
energy independent mechanism. However, in last decade it has become more 
evident that endocytosis is the preferred mechanism for internalization of cargo-
attached CPP-s.78 Most probably different CPP-s and CPP-cargo conjugates use 
different internalization mechanisms or even multiple combinations of these 
mechanisms.79  
During the last decade, the number of known CPP sequences has increased 
rapidly, and it still continues to grow. The novel CPP-s derived from well 
established proteins are often developed to have the shortest possible peptide 
sequences capable of translocation through the plasma membrane.8  
5
 Ta
bl
e 
2.
 E
xa
m
pl
es
 o
f C
PP
-s
 a
nd
 th
ei
r c
la
ss
ifi
ca
tio
n 
 Pr
ot
ei
n 
de
ri
ve
d 
C
PP
-s
 
C
PP
 
Se
qu
en
ce
 
O
ri
gi
n 
R
ef
er
en
ce
s 
Pe
ne
tra
tin
 
R
Q
IK
IW
FQ
N
R
R
M
K
W
K
K
a  
D
ro
so
ph
ila
 h
om
eo
pr
ot
ei
n 
A
nt
en
na
pe
di
a 
 
80
 
TA
T 
(4
8–
60
) 
G
R
K
K
R
R
Q
R
R
R
PP
Q
 
H
um
an
 im
m
un
od
ef
ic
ie
nc
y 
vi
ru
s t
yp
e 
1 
(H
IV
-1
) T
A
T
81
 
pV
EC
 
LL
II
LR
R
R
IR
K
Q
A
H
A
H
SK
a  
M
ou
se
 p
ro
te
in
-V
E-
ca
dh
er
in
 
82
 
V
P2
2 
N
A
K
TR
R
H
ER
R
R
K
LA
IE
R
 
H
um
an
 h
er
pe
s s
im
pl
ex
 v
iru
s p
ro
te
in
 
83
 
 C
hi
m
er
ic
 C
PP
-s
 
C
PP
 
Se
qu
en
ce
 
O
ri
gi
n 
R
ef
er
en
ce
s 
M
PG
 
c G
A
LF
LG
FL
G
A
A
G
ST
M
G
A
W
SQ
PK
K
K
R
K
V
b  
H
IV
 g
p4
1 
an
d 
SV
40
 T
-a
nt
ig
en
 
84
 
Pe
p-
1 
K
ET
W
W
ET
W
W
TE
W
SQ
PK
K
K
R
K
V
b  
N
LS
 fr
om
 S
V
40
 la
rg
e 
T-
an
tig
en
 a
nd
 re
ve
rs
e 
tra
ns
cr
ip
ta
se
 o
f H
IV
 
85
 
Tr
an
sp
or
ta
n 
G
W
TL
N
SA
G
Y
LL
G
K
IN
LK
A
LA
A
LA
K
K
IL
a  
G
al
an
in
 a
nd
 m
as
to
pa
ra
n 
86
 
TP
10
 
A
G
Y
LL
G
K
IN
LK
A
LA
A
LA
K
K
IL
a  
G
al
an
in
 a
nd
 m
as
to
pa
ra
n 
87
 
M
91
8 
c M
V
TV
LF
R
R
LR
IR
R
A
C
G
PP
R
V
R
V
 
Th
e 
tu
m
or
 su
pp
re
ss
or
 p
ro
te
in
 p
14
A
R
F 
88
 
 Sy
nt
he
tic
 C
PP
-s
 
C
PP
 
Se
qu
en
ce
 
O
ri
gi
n 
R
ef
er
en
ce
s 
O
lig
oa
rg
in
in
e 
(R
) n
d  
C
he
m
ic
al
ly
 sy
nt
he
si
ze
d 
po
si
tiv
el
y 
ch
ar
ge
d 
se
qu
en
ce
 
89
 
M
A
P 
K
LA
LK
LA
LK
A
LK
A
A
LK
LA
a  
C
he
m
ic
al
ly
 sy
nt
he
si
ze
d 
am
ph
ip
at
ic
 p
ep
tid
e 
90
 
C
A
D
Y
 
G
LW
R
A
LW
R
LL
R
SL
W
R
LL
W
R
A
b  
PP
TG
1-
de
riv
ed
, t
ry
pt
op
ha
n-
ric
h 
pe
pt
id
e 
91
 
a a
m
id
e;
 b c
ys
te
am
id
e 
m
od
ifi
ca
tio
n;
 c a
ce
ty
l m
od
ifi
ca
tio
n;
 d n
=6
–1
2d
   
 
19 
The utilization of CPP-s as therapeutic drug delivery vectors comprises both 
active and passive targeting mechanisms.6 Passive targeting can be charac-
terized as conditional mechanism that exploits extracellular properties of the 
tumor tissues including high levels of matrix metalloproteases and the pH 
differences between the tumor and normal tissues (Figure 1. A, B). Following 
this strategy CPP and cargo internalize into the cell only after tumor-specific 
extracellular enzymes cleave the CPP-shielding domain, revealing the CPP.92 
Alternatively the CPP can be revealed upon the lower pH environment, typical 
for the tumors.93 This pH-dependent CPP activation leads to the cargo specific 
internalization into the tumor cells.  
The active or affinity based targeting mechanism relies on the binding 
activity of tumor-specific homing peptides94, 95 and antibodies.96 Selective CPP-
cargo internalization takes place after the specific recognition of tumor cells by 
the antibodies or after the tumor-specific binding of the homing peptides 
(Figure 1. C, D).  
 
 
Figure 1.  Tumor-targeting strategies of CPP-based drug delivery vectors. A. protease-
dependent CPP activation. CPP and cargo intracellular internalization occurs when 
tumor-specific extracellular enzymes cleave the CPP-shielding domain; B. pH-depen-
dent CPP activation. Under the lower pH conditions the CPP can be revealed from the 
CPP-shielding domain leading to the rapid internalization of CPP-cargo vector; C. 
antibody-dependent tumor targeting is based on the specific recognition and binding of 
the antibodies to the tumor cells; D. tumor targeting by homing peptides relies on the 
affinity of the homing sequences to the specific receptors of the tumor cells.6  
 
 
Most CPP-s are able to penetrate the cells regardless of the cell type and 
proliferation stage, which is a great advantage especially when the delivery to 
hard-to-reach tissues (like the brain or into the parenchyma tissue, beyond blood 
vessels) is considered. The specificity of CPP-based drug delivery vectors can 
be improved by incorporating novel targeting strategies, for instance, homing 
peptide sequences determined by in vitro, in vivo or ex vivo phage display 
methodology.97 The studies of Ruoslahti and Laakkonen have described the 
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development of homing peptides, which recognize the molecular alterations in 
the vasculature of different organs and the tumors.98–101 The tumor-targeted 
peptide sequences were identified by using in vivo phage displayed peptide 
libraries and applied further for tumor-targeting therapies, significantly en-
hancing the efficacy of anticancer drugs.102 The detected sequences, capable of 
specific penetration activity in a certain cell types, are attractive vehicles for 
targeted drug delivery.103–107 
 
 
1.3. Identification of tumor targeting sequences using 
phage display technology 
The majority of pathological conditions, including tumors, diabetes, athero-
sclerosis, and inflammatory diseases are accompanied by the upregulation of 
disease-specific molecules on the endothelium of the affected tissues. For 
instance, during tumor progression, many vascular changes take place 
contributing to the process of angiogenesis, important for the enhanced blood 
supply of the growing tumors.108 Molecular changes that occur during the pro-
cess of vascular rearrangement can be profiled by using phage display techno-
logy. Phage-displayed random peptide libraries enable to map regional and 
disease-specific differences in the vasculature.109  
Initial studies utilizing phage display libraries or epitope libraries were per-
formed in vitro, where the peptide ligands were searched against the immobi-
lized antigen or cell-specific targets.110 Thereafter phage display was applied in 
vivo in order to identify the tumor vasculature homing peptides for anticancer 
therapy.103 Further in vivo studies have proven the fact that not only tumor 
vasculature, but also normal organs and cells can be targeted using the peptide 
sequences identified by in vivo phage display technology.101, 111 It was found 
that each normal tissue expresses its own specific set of cell-surface proteins 
and carbohydrates on vascular endothelial cells, that can be recognized by 
phage display screening and that constitute a vascular “zip code” system. These 
molecules act as novel biomarkers of vascular heterogeneity, being expressed 
by the normal vasculature and up- or downregulated in tumors.109 
The identification of tumor-targeting peptides has employed the advanced 
phage display technology, also known as biopanning. The biopanning method 
utilizes phage display approach, where the cells or the tissues of interest are 
exposed to a large, randomized library expressed on the surface of T7 or 
filamentous phage (M13) particles.112 The phage display library usually consists 
of billions of peptide sequences, representing a pool sufficient in size and 
diversity for the identification of the peptide sequences specific for a variety of 
target molecules.113 After exposure, the phage binds to the target cell and the 
non-relevant phage are removed. The remaining phage are released from the 
cells and expanded in bacteria, and selected again reexposing to the target of 
interest. The whole process can be repeated several (6–10) times in order to 
achieve the adequate enrichment with the relevant clone phage. The peptide 
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sequence carried as a fusion protein by this phage can be further identified by 
the peptide sequencing.112  
In the in vivo phage display the peptide library expressing phage are injected 
into the tail vein of a mouse and allowed to circulate for 5–15 min. Thereafter 
the organ of interest is removed and the bound phage is rescued and amplified. 
The whole process is repeated several times (biopanning).109, 113 Biopanning 
using phage display can be performed in cell culture, in animals or using the 
combination of in vitro and in vivo approaches.112, 113 
The combination of ex vivo and in vivo phage display screening methods can 
be applied for the detection of novel tumor-targeting sequences.114 According to 
this strategy the phage library is exposed to the cells prior isolated from the 
target tissue in order to enrich for peptides binding all cells in the tissue. 
Thereafter the phage library is introduced into the mouse blood circulation in 
order to screen for the peptide sequences, capable of specifically targeting the 
organs of interest. The advanced ex vivo/in vivo phage display approach allows 
detection of the homing peptide sequences for more effectively targeting the 
tissue of interest.115–117 
 
 
1.4. Cytotoxicity of CPP-s 
CPP-s play an important role in eukaryotic, prokaryotic and viral biology, being 
evolutionarily optimized on the one hand as killing agents and on the other as 
non-toxic cytosolic delivery agents. These biological properties of CPP-s 
encouraged the rapid development of CPP-based therapeutics either for 
antimicrobial, anticancer or for cytoprotective, anti-inflammatory or diagnostic 
purposes. Most CPP-s are cationic peptides, capable not only of translocation 
themselves but also of the intracellular delivery of various bioactive cargos. 
This implies an interaction with the plasma membrane, which can result in 
membrane disturbance. The combination of cationic and membrane-active 
properties leading to membrane perturbation is also the characteristic of 
antimicrobial peptides, which also belong to the group of cationic peptides.118 
Moreover, the derivation of CPP-s is also essential (Table 2). For example, 
some CPP-s such as pVEC,82 are derived directly from membrane proteins and 
are less toxic, whereas others such as transportans,86 originate from membrane 
lytic proteins and are designed to have high amphipathic properties can disturb 
the plasma membrane.90 The monitoring of CPP-s regarding their possible 
cytotoxic side effects on non-targeted membranes is of central importance, 
especially when the peptides are under consideration for therapeutic applica-
tions: gene therapy, cancer treatment.  
 Toxicity analysis of the peptide-based delivery agents is performed in most 
of the studies, although only a few studies comparing the toxicity of different 
classes of CPP-s under similar conditions are available.119–122 The presence and 
the origin of cargo may influence translocation mechanisms and the efficiency 
of the peptide-cargo conjugate, and also the toxicity may differ from that 
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exerted by the peptide alone. Several independent studies demonstrate that the 
conjugation of different cargos to the CPP reduces the toxicity produced by 
CPP alone. Maiolo et al., showed that the incorparation of a tri- or tetra- peptide 
cargo to Arg7 and Arg7Trp diminished the intrinsic toxicities of Arg7 and 
Arg7Trp alone.123 Jones et al., compared the toxicities of rhodamine-labelelled 
and unlabelled pAntp (43–58), pTAT (48–60), TP10, and Arg11, and their 
conjugates with NBD peptide cargo in A549 cells.120 The CPP-NBD or its 
scrambled sequence increased the toxicity of TP10 and pTAT (48–60), 
decreased the toxicity of Arg11 and had no effect on pAntp (43–58) response. 
One of the examples of negative influence on the cellular viability produced by 
cargo can be the conjugation of fluorophores such as carboxyfluorescein or 
tetramethylrhodamine to the peptides commonly utilized in order to monitor the 
internalization of the CPP-s. In their study El-Andaloussi et al., recently showed 
that the attachment of the carboxyfluorescein to CPP increases the cytotoxicity 
of the peptide.122 Similarly, Cardozo et al., showed that the cytotoxicity of TAT 
(48–57) and penetratin was higher for CPP conjugates with larger cargo 
peptides then for those unlabelled or with smaller cargo.119 Increased 
cytotoxicity of fluorescently labelled CPP-s was also reported by Dupont et al., 
whereby the conjugation of carboxyfluorescein to penetratin remarkably 
enhanced plasma membrane leakage in MDCK cells, while the biotin-labelled 
or unlabelled peptides showed no influence on cellular viability.124 
 
 
1.5. Innate immune response and immunogenicity  
of drug delivery agents 
The administration of almost any foreign macromolecule to an animal can elicit 
the immune response. Innate immunity comprises a variety of induced mecha-
nisms to clear the organism from foreign, potentially dangerous molecules. 
These mechanisms are well regulated by pathogen-recognition receptors of 
macrophages, neutrophils and dendritic cells that are able to discriminate 
between the molecules present on the normal cells and infectious foreign 
ligands such as mannose-rich oligosaccharides, peptidoglycans and lipopoly-
saccharides from the bacterial cells as well as unmethylated DNA, common for 
many pathogens. Once activated, the immune cells secrete pro-inflammatory 
chemokines and cytokines in turn activating naive T-lymphocytes and inducing 
the adaptive immune response.125, 126 
Although the majority of therapeutic drug delivery agents themselves are 
generally considered to be non-toxic and non-immunogenic, the size and the 
surface characteristics of cargo-assembled complexes or nanoparticles can 
affect the protein adsorption on the surface of these macromolecules in the 
blood stream.127, 128 The proteins that can specifically adsorb on the surface of 
the nanoparticles may address their uptake to the certain cell types including the 
immune cells.127, 129, 130 As a result, a cascade of immune responses can be 
initiated, attracting increased numbers of macrophages and triggering phago-
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cytosis and releasing cytokine signalling molecules, which further stimulate a 
systemic immune response.130–133 
Various in vitro assays have evaluated the effect that nanomaterials can 
produce on immune cell uptake, viability and cytokine expression. For instance, 
Shukla et al., examined the effects that 3–8 nm gold nanoparticles (AuNP) 
produced on the RAW264.7 macrophage cell line.134 They demonstrated that 
AuNP-s at the concentration of 100 μM and of the certain size do not reduce 
viability and do not stimulate inflammatory cytokines such as TNF-α and IL-1 
β. Yen et al., evaluated AuNP effect on J774 A1 macrophages testing different 
size ranges: 2–4 nm, 5–7 nm and 20–40 nm.135 They showed that AuNP 
triggered the inflammatory response, producing higher levels of IL-1 β, IL-6 
and TNF-α cytokines within 6 h compared to controls. TNF-α and IL-6 
expression was higher than in controls after 48 h of incubation with the particles 
with smaller size range, demonstrating the importance of the particle size for the 
immunological response. One of the explanations can be the difference in the 
adsorption of serum proteins to the particles of different sizes, although the 
mechanism of this effect remains unclear.136 Additionally, undesired toxicity 
can be mediated through interactions of the nucleic acids with the proteins. 
These effects can be sequence-dependent, as for interaction of nucleic acids 
with Toll-like receptors (TLR-s), or sequence-independent.137 For example, 
RNA molecules can also affect TLR-s 3, 7, and 8, eliciting undesired immune 
stimulation that manifests as hyperplasia in lymphoid organs and mononuclear 
cell infiltrates in non-lymphoid organs.138, 139 
Application of CPP-s for drug delivery has shown to be of great advantage 
as synthetic peptides contain less than 30 amino acids and show no evidence of 
cytotoxicity, immunogenicity or oncogene activation.140 However, the research 
into biological side effects of cationic and amphipathic peptides has still 
received great attention.141 Several independent studies on biological side 
effects of cationic and amphipathic peptides suggest that amphipathic peptides 
such as TP10 affect cellular metabolism already at a concentration of 5 μM,142 
whereas the cationic peptides such as TAT are not cytotoxic in vitro even at 
concentrations up to 400 μM.143 However, in vivo studies by the same group 
indicated some mild cytotoxic effect on a rabbit’s eyelid after 7 days of 
application of TAT peptide. Similarly, poly-Arg peptides also did not induce 
any cellular toxicity at siRNA/peptide ratio of negative/positive charges of 
40.143–145 The studies indicate applicability of CPP-s for anticancer therapy, 
without the non-specific activation of the immune system.3 However, there are 
still a number of studies describing the activation of macrophages, and recruit-
ment of leukocytes, which leads to the systemic induction of the immune 
response by the therapeutic drug delivery agents in vivo.136, 146–149 Therefore, the 
in vivo studies that characterize the immunological response to the drug delivery 
agents are very essential. 
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1.6. Prediction of CPP-s  
The opportunity to predict the cell-penetrating functions of novel peptide 
sequences provides new possibilities for the development of novel peptide-
based delivery systems. The predictions, based on such important CPP sequence 
characteristics as abundance of basic amino acids, length and ability to form 
secondary structures have helped to determine several effective CPP-s. How-
ever, those predictions were often quite imprecise. For instance, uptake 
efficiency can vary widely between the different laboratories: from 100 fold 
enrichment of the peptide in the cytoplasm to equilibrium concentrations, 
comparable to the extracellular concentrations.150, 151 The prediction of CPP 
functionality requires the independent and precise calculations of several 
peptide structure-dependent parameters that contribute to the CPP characte-
ristics. Such analyses would not be an easy task, especially when taking into the 
account that various parameters can differ between the cell lines or due to 
different methods of measurement. In order to simplify the analysis it would be 
reasonable to reduce the number of predicted variables assuming that the CPP 
properties are bulky and does not depend on specific motifs, but rather on the 
net properties of the amino acid residues in the peptide.151 Thus the properties 
important for the membrane penetration have been established.152, 153 As the 
membrane surface contains charged and neutral groups of the lipid layer it 
would be reasonable to assume that the electrostatic and hydrophobic inter-
actions should be essential for the initial process of cellular penetration.154, 155 
According to their structures the CPP-s can be classified in three different 
groups: the peptides with low amphipaticity like penetratin80 and TAT,75 the 
peptides with high amphipaticity like MAP90 and transportan,86 and the peptides 
in which the charged and hydrophobic residues are separated longitudinally in 
the chain, such as pVEC82 and Pep-1.85 Most probably the peptides, which 
belong to different groups internalize inside the cells following different endo-
cytotic pathways. The quantitative structure-activity relationship analysis 
(QSAR) for the peptides is generally performed on the amino acid residue basis, 
interpreting the physico-chemical characteristics of the compounds into sets of 
descriptor variables. Three descriptive scales for the twenty natural amino acids 
z1, z2 and z3156 were first introduced by Hellberg et al. The scales were settled 
down using such physicochemical variables as molecular weight, pKa and 
partition coefficients. Z-scales quantify the structural variation within a group of 
related peptides organizing the z-scales according to the particular amino acid 
sequence.  
In 1998, Sandberg et al., in search for the parameters that would allow 
predicting the biological activity of peptides presented five-descriptor sets z1-
z5, collecting a vast amount of variables for total 87 coded and non-coded 
amino acids.157 The bulk of the amino acids corresponding to the number of 
heavy atoms (C, N, S and O) in the amino acids side-chains was also utilized. 
Additionally, the net donated hydrogen bonds of the amino acid, which were 
obtained by the calculation of accepted hydrogen bonds of the side-chains 
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subtracted from the donated hydrogen bonds was also shown to be very impor-
tant in order to predict the cell-penetrating activity of the newly designed 
peptides.158 
Recently Dobchev et al., developed the Artificial Neural Network-based 
computational model (ANN) using principle component analysis (PCA) for the 
prediction of CPP-s, which internalize by similar mechanisms.159 Application of 
ANN and PCA allowed predicting the penetrating capability of 101 studied 
peptides with 83 % accuracy. Moreover further optimization of the analyzed 
data sets improved the prediction up to 100 %. 
The ANN model comprises the input layer consisting of six molecular 
descriptors D1-D6, derived from 3D peptide structures: topographic electronic 
index for all bonds, difference in charged partial surface areas, Schultz average 
vertex, molecular weight, hydrogen acceptor dependent charged surface area, 
difference (positive-negative) in charged partial surface area. These descriptors 
were determined by performing PCA analysis using STATISTICA160 software 
(StatSoft Inc., USA). Additionally the ANN model also contains hidden layers 
and an output layer where a single neuron related to the cell penetration. 
 
 
1.6.1. CPP prediction algorithm  
The mathematical model to predict CPP sequences was introduced by Hällbrink 
et al., in 2005. This model was assigned to establish the CPP sequences using 
either already existing proteins or random peptide sequences.158 The principle of 
this prediction model is also based on z-descriptors reflecting certain chemical 
and physical properties of each amino acid157 and providing a well-documented 
and accurate platform for CPP prediction. Utilizing the Sandberg’s z-scales, 
Hällbrink et al., developed a CPP prediction algorithm, analyzing the bulk 
property values (zΣ/n), for the set of 24 cell-penetrating and 17 non-penetrating 
sequences. The possibility to perform in silico predictions using a CPP pre-
diction algorithm would be of great advantage,161 however, the main drawback 
would be its inability to consider the order of the amino acid residues in the 
peptide backbone calculating only the overall sum of the residues in the 
sequence. The algorithm allows obtaining equal predictions for CPP-s as well as 
for their inversed and scrambled analogues, which might not internalize into the 
cells that effectively.158 
Nevertheless several reports were published recently describing the success-
ful utilization of the prediction algorithm for the detection of the biologically 
active CPP-s. The study of Howl et al., confirmed the applicability of a CPP 
prediction algorithm by generating cytochrome C (Cyt C) protein-derived 
analogue, capable of cellular internalization and the reduction of the viability of 
cancer cells.162 Using a CPP prediction algorithm Johansson et al., designed 
p14ARF protein-derived 22 amino-acids-long peptide, which was prone to 
translocation inside the breast cancer cells inducing apoptosis.163 
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1.7. Apoptosis 
Apoptosis is an evolutionarily conserved energy-dependant process of pro-
grammed cell death that is important for normal development of eukaryotic 
organisms, the maintenance of tissue homeostasis and an effective functioning 
of the immune system.164 In contrast to necrosis, apoptosis does not result in 
inflammation because the damaged cells do not disintegrate and expose their 
interior to the neighbouring cells, but form the apoptotic bodies, which are 
further phagocytosed by the surrounding cells.165 During the last few decades, 
the process of apoptosis has received significant attention because of it involve-
ment in such widespread diseases as cancer and cardiovascular disorders. 
Therefore, the identification of the mechanisms standing behind the apoptosis is 
of particular interest. Many different pathways are involved in the induction of 
apoptosis however two major pathways are commonly defined: death receptor 
and mitochondrial pathways166 (Figure 2). Both pathways converge to induce 
the activation of caspases, the final executioners of cell death, although, it 
should be noted that caspase-independent forms of apoptosis have also been 
reported.167  
 
 
 
Figure 2. Death receptor and mitochondrial apoptotic pathways.168, 169 In response to 
different extra- or intracellular stress signals, p53 transactivates pro-apoptotic genes 
activating the death receptor pathway (CD95, TRAIL, Bid), or the mitochondrial 
pathway (Bax, Noxa, Puma, Cyt-C, APAF-1). The pathways induce the activation of 
caspase-9 and caspase-3 leading to apoptosis. 
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1.7.1. Death receptor pathway 
The death receptor or extrinsic pathway involves death receptors that are 
expressed on the surface of the cells and induce apoptosis upon ligand binding. 
Death receptors belong to the tumor necrosis factor (TNF) super family the best 
characterized of which are Fas170 (CD95/Apo1), TNF receptor 1171 (p55), 
TRAMP172, 173 (WSL-1/Apo3/DR3/LARD), TRAIL-R1174 (DR4) and TRAIL-
R2175 (DR5/Apo2/KILLER). Fas Ligand (CD95 ligand) binds Fas, TNF and 
lymphotoxin A bind to TNFR1176, TWEAK (Apo3 ligand) binds to TRAMP177 
and TRAIL (Apo2 ligand) is the ligand for both TRAIL-R1174 and TRAIL-
R2.178 Activated by ligand these receptors formed in an intracellular death 
domain DD, associate directly with Fas-associated death domain (FADD) or 
indirectly via TNFR-associated death domain176, 179 (TRADD). FADD further 
interacts with pro-caspase-8 forming a complex at the death inducing signalling 
complex (DISC), which induces the activation of caspase-8 and the activation 
of other downstream effector caspases. Caspase-8 in turn also triggers the 
intrinsic apoptotic pathway by cleaving the BH3 interacting domain agonist Bid 
and translocating to the mitochondria.180 In addition to the TNF death receptor 
family there are the decoy receptors DcR1, DcR2 and osteoprotegerin (OPG), 
which inhibit death signalling through the sequestration of ligand.176  
 
 
1.7.2. Mitochondrial pathway 
The mitochondrial or intrinsic pathway is activated in response to a variety of 
extra- and intracellular stress factors such as DNA damage, ischaemia and 
oxidative stress resulting in the activation of numerous apoptotic signals, which 
lead to cell death. The majority of anticancer drugs and irradiation also 
contribute to the activation of mitochondrial apoptotic pathway, which 
commonly starts with the permeabilization of the mitochondrial outer 
membrane. Although the mechanisms of this process remain unclear, it is 
suggested that the permeabilization can be either permeability transition (PT) 
pore dependent or independent.181 The opening of the PT pore triggers the 
dissipation of the proton gradient created by electron transport, causing the 
water entrance into the mitochondrial matrix, which results in swelling of the 
intermembranal space and rupturing of the outer membrane. These induces the 
release of several apoptogenic proteins181, 182 such as Cyt C,183 apoptosis 
inducing factor184 (AIF) and endonuclease G.185, 186 Cyt C together with 
apoptosis protease activating factor (APAF-1) and caspase-9 forms an 
“apoptosome”187 that in turn activates the effector caspases collectively 
mediating the apoptosis. AIF184 and endonuclease G186 mediate DNA frag-
mentation and subsequent chromosomal condensation. PT pore independent 
mitochondrial membrane permeabilisation is regulated by Bcl-2 family 
members, which can be subdivided into anti-apoptotic members such as Bcl-2 
and Bcl-xL and pro-apoptotic members such as Bax, Bak, and Bok, Bad, Bik, 
Bid, Puma, Bim, Bmf and Noxa.188–192 
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1.7.3. Tumor suppressor protein p53 
Elucidation of the function of many mutated gene products supports the 
importance of the proper regulation of cellular pathways. Cells continuously 
respond to different external and internal signals through oncogenes and tumor 
suppressor genes, which both control the crucial steps in the cell cycle: 
transitions from G0/G1 (resting) stage to S (replicating) stage, inhibit cell growth 
and induce apoptosis in response to cellular stress or other stimuli.193 Both 
oncogene and tumor suppessor gene products are in most cases involved in the 
signalling cascades and are integrated in protein interaction networks.194 The 
heterogeneity of tumor cells that comes from the variety of mutations makes it 
difficult to define the most promising drug targets. However, the proteins that 
are functionally participating in tumor formation and progression can provide a 
source of potential therapeutic targets as they are functionally crucial for cancer 
cells and are at least temporarily not vital for normal cells.195 One such potential 
anticancer therapeutic target is p53, which in normal cells is present at low 
levels being inhibited by murine double minute-2 (MDM2) or the human homo-
logue196 (HDM2) protein. Following apoptotic signals, p53 is normally 
activated during the mitochondrial apoptotic pathway. Activation of p53 
involves stabilization of the protein by post-translational modifications 
disrupting the interaction between p53 and MDM2. p53 mediates the expression 
of APAF-1 and certain pro-apoptotic Bcl-2 family members197 as well as 
eliciting transcriptional independent cell death pathways.198, 199 Being a 
transcription factor p53 suppresses the tumorigenesis, and is mutated in over 50 
% of tumors.166 The pro-apoptotic activity of p53 can be characterized as 
transcriptional dependent and independent, because it induces transcription of 
the genes involved in both extrinsic (CD95 and DR5) and intrinsic (PUMA, 
Bax, Bid) pathways. Moreover, the cytoplasmic p53 inhibits the pro-survival 
activity of Bcl-2 and Bcl-XL and/or activates the pro-apoptotic Bax, indepen-
dently of its transcriptional activity.199 As the p53 is pleiotropic, being involved 
in the regulation of cellular development,200, 201 metabolism,202 mitosis203, 204 and 
reproduction205 many anticancer strategies aim to restore the p53 activity in 
tumors in order to induce apoptosis in cancer cells.206 
 
 
1.8. Mimicking CPP-s 
Modulation of the protein-protein interactions using mimicking proteins would 
be beneficial for the regulation of intracellular procesess. The main drawback 
for the application of such proteins is their complex production and inability to 
penetrate the cell, where the most protein interactions occur. Therefore, the 
conjugation of biologically active proteins and peptides to the CPP-s would 
facilitate their entry.207 The outcomes of protein-protein interactions are not 
always easy to predict as the examined protein can either bind to the target 
protein producing an effect or it can block protein-protein interactions by 
inducing conformational changes, which can either activate or inhibit the target 
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protein functions. Similarly, a peptide designed to mimic a protein can also 
activate or inhibit the interactions, depending on the function of the protein 
from which it is derived. Regarding the activating versus inhibiting mimicking 
peptides, the activating mimicking peptides would be more pharmacologically 
advantageous as lower concentrations are needed to produce the effect. 
Inhibitory mimicking peptides compete with the native ligands therefore higher 
doses are needed to produce the effect, which can also induce the non-specific 
side effects, namely immunogenicity. Additionally, since the mimicking 
peptides represent short fragments from the original protein, to acquire all the 
interacting interfaces and regulatory sites of the full-length protein would be 
quite complicated.207 
An example of protein-protein interaction inhibiting peptide is VIVIT 
peptide, which inhibits the calcineurin-NFAT interaction,208, 209 and shepherdin, 
which in turn blocks the surviving-Hsp90 interaction.210 Generally the thera-
peutic targets of mimicking peptides that inhibit protein-protein interactions are 
focused on the suppression of cancer cell progression.207  
Fulda et al., described the conjugation of the mitochondrial caspase activator 
SMAC-derived, 7 amino acid-long peptide with TAT. This conjugate allowed 
sensitizing the tumor cells to the anticancer treatment in the intracranial 
xenograft model.211 The conjugation of TAT to the cytotoxic cyclin-dependent 
kinase inhibitor p21WAF1/CIP1 -derived mimicking peptide resulted in the 
translocation of the peptide inside the U251 human glioblastoma cells inhibiting 
their proliferation.212  
Restoration of p53 functions would also lead to the induction of apoptosis in 
tumor cells. Selivanova et al., conjugated penetratin to the C-terminus of p53 
peptide and demonstrated the activation of specific DNA binding induced by 
fusion, which restored the transcriptional trans-activating function of the mutant 
p53 protein in the living cells.213 Penetratin-p53 fusion peptide induced 
apoptosis both in mutant and in wild-type p53-bearing cancer cell lines, 
whereas normal cells remained non-affected.214 Furthermore Araki et al., 
generated peptides using TAT, oligoarginine and FHV conjugating them to the 
C-terminal domain of p53. As a result the application of oligoarginine-p53 and 
FHV-p53 significantly inhibited bladder cancer cells prolifiration, decreased 
tumor burden and prolonged survival in bladder cancer xenografts.215  
Several studies have reported the successful application of CPP-s in MDM-2 
protein suppression in cancer cells. Kanovsky et al., designed p53 MDM-2-
binding region-derived peptides linked to penetratin in order to conduct cellular 
internalization.216 The competitive binding to MDM-2 by a p53 mimicking 
peptide subsequently preserved the intracellular p53 activity, prolonging its 
half-life in pancreatic cells. The treatment did not influence the growth of non-
cancer cells. These observations were further confirmed in vivo by Harbour et 
al., who showed that TAT-MDM-2-inhibiting fusion peptide induced the accu-
mulation of p53, and preferential apoptosis in tumour cells, but not in normal 
cells, inducing no toxic side effects in vivo.217 Similar results have been 
obtained using penetratin fusion with MDM-2-binding residues.218  
8
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For therapeutic effect, the combination of the effector and the CPP in the 
same peptide sequence is preferred. This strategy would eliminate the 
requirement of the additional conjugation to the CPP making the production 
easier. Cyt C is an important protein in the electron transport chain of the 
mitochondria and is released in response to the apoptotic stimulus. Howl et al., 
discovered that the Cyt C protein also contains sequences possessing the CPP 
properties.219 The mimicking peptides Cyt C86–101 and Cyt C77–101 were found to 
reduce the cancer cell viability, inducing DNA fragmentation and caspase-3 
activation, which are the hallmarks of apoptosis.  
Cell cycle control mechanism disorders are common for all types of cancers. 
p14ARF, MDM2 and p53 belong to the same regulatory pathway and are 
altered in all the tumors. p14ARF suppresses tumor progression by inhibiting 
the MDM2 protein leading to the activation of p53 and the induction of 
apoptosis.220, 221 Johansson et al., generated four p14ARF protein-derived 13–37 
amino-acid-long peptides, all designed from the N-terminal region.163 The 22 
amino-acid-long N-terminal peptide denoted as ARF(1–22) was found to be a 
CPP, capable of inducing apoptosis in breast cancer cell lines MCF7 and MDA-
231 MB by mimicking the functions of the full-length p14ARF protein.  
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2. AIMS OF THE STUDY 
 
The thesis is focused on the characterization of immunogenic and cytotoxic 
activities of PepFect (PF) peptides, on cytotoxic and apoptotic activities of 
newly designed cell-penetrating p53 analogues, on the development of peptide-
based tumor-targeted drug delivery vector gHoPe2 and on the evaluation of 
nucleic acid delivery efficiency of the N-terminally stearylated CPP-s. 
 
Paper I  
The aim of the study was to analyze the cytotoxic and immunogenic activity of 
PF peptides and PF/nucleic acid complexes in vitro and in vivo and to compare 
it with the cytotoxic and immunogenic activities of unmodified TP10, TAT 
(48–60) and stearyl-(RxR)4 and the widely used lipofectamine transfection 
reagents. 
 
Paper II 
The aim of the study was to design and synthesize short p53-derived cell-
penetrating protein analogues and to analyze their cytotoxic and apoptotic 
activity in breast cancer cell lines. 
 
Paper III  
The aim of the study was to develop a novel glioma-targeted drug delivery 
vehicle based on a new glioma-specific homing peptide sequence conjugated to 
a CPP. 
 
Paper IV 
The aim of the study was to evaluate the effect of N-terminal stearylation of the 
(RxR)4 peptide on plasmid and oligonucleotide delivery and to estimate the 
possible cytotoxic effect of peptides/nucleic acid complexes in vitro comparing 
it with the cytotoxic activity of the lipofectamine transfection reagent. 
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3. METHODOLOGICAL CONSIDERATIONS 
 
Methods and materials used in the thesis are described extensively in respective 
papers, therefore only theoretical and practical aspects of the methods will be 
discussed in this section. 
 
 
3.1. Choice and design of CPP-s  
The sequences of all CPP-s studied in this thesis are presented in Table 3. 
In Paper I, cytotoxicity and immunogenicity of PF3, PF4 and PF6 peptides 
as well as peptide/nucleic acid complexes were analyzed in vitro and in vivo. 
The capability to induce immunogenicity and in vivo toxicity can limit the 
application of CPP-s as drug delivery vectors in clinical settings. We estimated 
the influence of the PF delivery agents on the immune response by measuring 
caspase activity, cytotoxicity and cytokine release in vitro and in vivo. Several 
well-established peptides such as TAT (48–60), stearyl-(RxR)4, transfection 
reagents Lipofectamine™ 2000 and Lipofectamine™ RNAiMAX as well as 
LPS were used in parallel in this experiments in order to provide a comparison 
with the immunogenic profile of PF. 
Previous studies have shown that the rational design by using QSAR-based 
algorithm allows creating protein analogues in which cell-penetrating and 
biological activities are organized within the primary sequence. In Paper II we 
designed and synthesized short p53 analogues Peptide4 and Peptide5, which 
were capable of penetrating breast cancer cells and induce apoptosis. By using 
the primary amino acid sequence of p53 available at NCBI Human Protein 
Database and a CPP prediction algorithm we generated potential CPP sequences 
thereafter utilized for apoptotic analyses. 
In order to improve chemotherapeutic activity of antineoplastic agents the 
incorporation of the tumor-specific targeting sequences into a CPP-based drug 
delivery vectors has been studied. In Paper III, novel tumor-selective CPP-
based drug delivery platform gHoPe2 was developed. The novel drug delivery 
vector comprises a glioma-specific peptide sequence that has been covalently 
conjugated to the CPP pVEC and the commonly used anticancer drug 
doxorubicin. The gHoPe2 drug delivery vehicle and unmodified doxorubicin 
were utilized for the treatment of glioblastoma in vitro and in mouse xenografts. 
In Paper IV, (RxR)4 and oligoarginine (Arg9) CPP-s were used for the 
delivery of plasmid DNA and splice-correcting oligonucleotides (SCO-s) in 
vitro. The main problem for CPP-s taken up by endocytic pathways is the 
escape from endolysosomal compartments. The introduction of a stearyl group 
in the structure of CPP-s was utilized to overcome the problem of endosomal 
entrapment. 
 
 
 
33 
Table 3. Sequences of CPP-s used in this thesis 
Names Sequence Reference 
Transportan 10, TP10 AGYLLGKINLKALAALAKKIL-NH2 87 
TAT (48–60) GRKKRRQRRRPPQ-NH2 81 
Stearyl-(RxR)4 aRxRRxRRxRRxR-NH2 59 
Stearyl-Arg9 aRRRRRRRRR-NH2 222 
PepFect3, stearyl-TP10, PF3 aAGYLLGKINLKALAALAKKIL-NH2 58 
PepFect4, stearyl-TP10, PF4 AGYLLGKbINLKALAALAKKIL-NH2 223 
PepFect6, PF6 aAGYLLGKcINLKALAALAKKIL-NH2 57 
Peptide1, p53 (369–382) GKKHRSTSQGKKSKL-NH2 224 
Peptide2, FAM-p53(369–
382)d 
dGKKHRSTSQGKKSKL-NH2 224 
Peptide3, Stearyl-(Lys3-εNH-
Stearyl)-p53(369–382)b,d 
dGKKaHRSTSQGKKSKL-NH2 224 
Peptide4, Stearyl-p53(369–
382)d 
dGKKHRSTSQGKKSKL-NH2 224 
Peptide5,(Lys3-εNH-Stearyl)-
p53(369–382)b  
GKKbHRSTSQGKKSKL-NH2 224 
pVEC LLIILRRRIRKQAHAHSK-NH2 82 
gHo NHQQQNPHQPPM-NH2 95 
FAM-pVEC dLLIILRRRIRKQAHAHSK-NH2 95 
FAM-gHo dNHQQQNPHQPPM-NH2 95 
FAM-pVEC-gHo (FAM-
gHoPe2) 
dLLIILRRRIRKQAHAHSKNHQQQNPH
QPPM-NH2 
95 
FAM-gHo-pVEC (FAM-
gHoPe3) 
dNHQQQNPHQPPMLLIILRRRIRKQAH
AHSK-NH2 
95 
Dox-pVEC-gHo (Dox-
gHoPe2) 
eXCLLIILRRRIRKQAHAHSKNHQQQN
PHQPPM-NH2 
95 
aN-terminal stearyl-modification; x – aminohexanoic acid (Ahx); bstearyl modification 
Lys3; cTrifluoromethylquinoline based derivative (Figure 3) conjugated to succinylated 
lysine tree; dstearyl or 5(6)-carboxyfluoresceinyl modification at N-terminus; 
edoxorubicin; X – succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate 
(SMCC) 
 
 
 
Figure 3. The structure of trifluoromethylquinoline 
9
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3.2. Prediction of CPP-s 
The sequences of the peptides presented in Paper II were designed using the 
CPP prediction algorithm-based program VFREQ27, developed by Hällbrink et 
al., in 2003.225 The program utilizes QSAR descriptor scales, which describe a 
composite of the physical characteristics of the amino acids contributing to the 
cell-penetrating function of the peptides. The CPP prediction program enables 
to perform analysis of the CPP functionality of naturally occurring peptides and 
de novo designed CPP-s. 
In Paper II, we generated short CPP fragments using the amino acid 
sequence of p53, available at NCBI Human Protein Database 
(http://www.ncbi.nlm.nih.gov/protein). The program searched for possible CPP 
sequences inside the defined search window. As a result a list of 100 peptide 
sequences total, with lengths ranging between 12–22, was generated. CPP 
efficacy was scored on a scale of 1–3, where score “1” represents the least and 
“3” the most potent CPP. 
The peptide sequence, which is derived from the lysine-rich domain of C-
terminus of p53 with the highest cell-penetrating prediction score, was chosen 
for further investigations. 
 
 
3.3. Peptide synthesis  
3.3.1. Solid-phase peptide synthesis (SPPS) 
All peptides used in this thesis were synthesized using solid-phase peptide 
synthesis (SPPS) strategy. First described in 1986 by Bruce Merrifield,226 SPPS 
is based on the repeated cycles of amino acid coupling and deprotection 
procedures, performed on a solid polymer resin. The side-chains of the amino 
acids are protected by special protective groups such as t-butyloxycarbonyl (t-
Boc) or t-butyl (tBu) in order to ensure that the activated carboxylic acid is 
reacting specifically with the α-amino group. The α-amino group of each amino 
acid is protected by either t-Boc or 9-fluorenylmethyl-oxycarbonyl (Fmoc) in 
order to prevent the non-coupled amino acids from reacting with each other. 
The α-amino protective group is removed subsequently before each coupling, 
while the side-chain protective groups remain on until the final cleavage of the 
peptide from the resin. 
In current studies all peptides were synthesized in stepwise manner on a  
0.1 mmol scale on an automated peptide synthesizer using Fmoc solid-phase 
peptide synthesis strategy227 with Rink-amide MBHA (methylbenzyl-
hydrylamine) resin as solid phase polymer to obtain C-terminally amidated 
peptides. The stearic acid was coupled manually to the N-terminus of the 
peptide by treatment of peptidyl-resins with 5 equivalent (eq.) stearic acid, 3 eq. 
HOBt and 3 eq. HBTU, 6 eq. DIEA in dimethylformamide/dichloromethane 
(1:1) overnight at room temperature. For synthesis of FAM-labelled peptides 
5(6)-carboxyfluorescein monomer was used and the coupling was carried out 
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manually by treatment of peptidyl-resin with 4 eq. of a 5(6)-carboxyfluorescein, 
4 eq. N-Hydroxybenzotriazole (HOBt) and 4 eq. N,N'-diisopropylcarbodiimide 
(DIC), 8 eq. N,N-diisopropylethylamine (DIEA) in DMF/DMSO (1:1; v:v) 
overnight at room temperature. After coupling the resin was washed 3 times 
with 20 % piperidine solution to remove the cross-linked carboxyfluorescein 
residues. The final cleavage was performed using standard protocol (95 % 
TFA/2.5 % TIS/2.5 % H2O) followed by product precipitation using diethyl 
ether and lyophilization using a vacuum pump. 
 
 
3.3.2. Purification and identification of synthesized peptides 
Peptides were purified using preparative reversed phase high pressure liquid 
chromatography (RP-HPLC) with C4 column and a 5–100 % acetonitrile/water 
gradient containing 0.1 % TFA. The correct product-containing fractions were 
identified by matrix-assisted laser desorption ionization time-of-flight (MALDI-
TOF) mass spectrometry using α-cyano-hydroxycinnamic acid as the matrix. 
 
 
3.3.3. Doxorubicin conjugation to CPP 
For preparation of doxorubicin conjugates, cysteine amino acid was added to 
the N-terminus, followed by the cleavage and purification of the peptides as 
described above. Doxorubicin was conjugated according to Liang et al., with 
minor modifications (Figure 4).228 Doxorubicin (2 mg) was dissolved in 500 μl 
of DMSO and then dispersed in 500 μl of PBS (pH 8.0) at the concentration of 
2 mg/ml followed by addition of 20 μl of triethylamine (TEA) and 200 μl of 
succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC,  
10 mg/ml). After incubation at a room temperature for 2 h the pH was adjusted 
to 5.5 using 2 M HCl and 300 μl of peptide solution (15 mg/ml) was added. 
Thereafter the mixture was incubated at room temperature for another 2 h. In 
order to remove non-conjugated doxorubicin, SMCC and TEA, the reversed-
phase purification using a gradient of acetonitrile/water containing 0.1 % TFA 
(5–100 % for 45 min) was carried out. The identity and purity of the obtained 
doxorubicin conjugates were confirmed by using MALDI-TOF mass 
spectrometry and analytical HPLC respectively. 
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Figure 4. Doxorubicin conjugation to gHoPe2 drug delivery vector228 (Paper III) 
 
 
3.4. Covalent and non-covalent strategies  
for cargo conjugation  
The conjugation of different cargos to the CPP can be performed following two 
main strategies: covalent conjugation based on the formation of covalent bond 
between the cargo and CPP, and non-covalent conjugation, which is possible 
due to electrostatic interactions. During the covalent conjugation the cargo can 
be coupled to the CPP using a reducible disulphide bridges. In the case of 
doxorubicin conjugation the coupling procedure with SMCC was performed 
beforehand. The SMCC contains two reactivities toward amines, through the 
succinimide group, and reactivity toward sulphhydryls, through the maleimide 
group. The chemical group N-hydroxysuccinimydyl (NHS) reacts in aqueous 
phase, optimally at neutral pH (7.5 (6.5–8.5)) or higher, on the amine functional 
group of doxorubicin, resulting in SMCC-doxorubicin formation. The 
maleimide group at neutral pH (6.5–7.5) reacts very specifically with the 
sulphhydryl group (-SH) of the cystein present in the CPP sequence. The 
reaction is rapid (a few minutes for cystein), but may require 1–2 h to be 
completed in certain conditions. The advantage of this approach is that the 
glutathione inside the cells cleaves the disulfide bridges and releases active 
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cargo from the conjugate. The main disadvantages of this strategy are its 
relative complexness, low synthesis yield and the necessity of extensive 
purification steps. 
The non-covalent strategy involves a co-incubation of CPP with nucleic acid 
cargo (plasmid, oligonucleotides or siRNA) at a specified charge or molar ratios 
resulting in nanocomplex formation. The principle of this procedure is 
electrostatic interactions between the positive charges of CPPs and the negative 
charges of nucleic acid. The advantage of the non-covalent strategy is the 
simplicity of manipulations and short preparation time of the procedure.  
In order to obtain PF/plasmid DNA complexes 0.5 μg of green fluorescent 
protein-expressing pEGFP-C1 plasmid was co-incubated with PF3 or PF4 at 
different plasmid/peptide charge ratios (CRs) 1:1 and 1:5 in MQ water in 1/10th 
of the final treatment volume (i.e. 30 μl). CRs were calculated theoretically, 
taking into account the positive charges of the peptide and the negative charges 
of the plasmid. The final concentration of PF3 or PF4 was 0.75 μM at CR 1:1 
and 3.75 μM at CR 1:5. Complexes were incubated for 1 h at room temperature. 
In order to obtain PF/siRNA complexes PF6 (100 μM stock solution) was 
mixed with HPRT1 siRNA (10 μM stock solution) in MQ water in 1/10th of 
final treatment volume (i.e. 30 μl), using peptide: siRNA molar ratios (MRs) 40 
and 30, siRNA 50 nM and 100 nM respectively. 
In order to obtain stearyl-(RxR)4 or Arg9/plasmid DNA complexes, 0.5 μg of 
pGL3 luciferase expressing plasmid was mixed with CPP-s at different charge 
ratios (CRs) (1:1–1:5) in MQ water in 1/10th of the final treatment volume (i.e. 
50 μl). CRs were calculated theoretically, taking into account the positive 
charges of the peptide and negative charges of the plasmid. For instance, final 
concentration of stearyl-(RxR)4 was 0.38 μM at the 1:1 CR.  
2′-OMe SCO-s were mixed with stearyl-(RxR)4 or Arg9 CPP-s at different 
molar ratios in MQ water in 1/10th of the final treatment volume (i.e. 50 μl). 
Complexes were formed for 1 h at room temperature and meanwhile the cell 
medium was replaced in 24-well plates to fresh serum-free DMEM (450 μl). 
Thereafter, complexes were added to each well.  
Complexes were incubated for 1 h at room temperature. In the case of 
Lipofectamine™ 2000 and Lipofectamine™ RNAiMAX (Invitrogen, Sweden), 
complexes were formed according to the manufacturer's protocol. Lipo-
fectamine™ 2000 and Lipofectamine™ RNAiMAX were used as positive 
control in all experiments. Formation and stability of all the peptide/nucleic acid 
complexes in the presence or absence of serum was confirmed by agarose gel  
(2 %) stained with EtBr (0.5 µg/ml). 
 
 
3.5. Cell culture 
Several immortalized cell lines were used in this thesis. The cell lines chosen 
for the experiments are commonly used in the CPP field and enable com-
parisons with previously published data. 
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3.5.1. THP-1 cell line 
Human acute monocytic leukemia cell line (THP-1) is commonly used as a 
model leukemia cell line in immunocytochemical analysis of protein-protein 
interaction, and immunohistochemistry. THP-1 cells are a monocyte-like cell 
line derived from a patient with acute monocytic leukemia and unlike other 
leukemic cell lines has a normal diploid karyotype. Derived from the peripheral 
blood of a one-year-old human male with acute monocytic leukemia, THP-1 
cells have Fc and C3b receptors and lack surface and cytoplasmic immuno-
globulins. In paper I, the THP-1 cell line was used as a model system for 
immune response studies in vitro as they are capable of IL-1 and TNF-α 
cytokine production when differentiated into macrophage-like cells using 
phorbol 12-myristate 13-acetate (commonly known as PMA). 
 
 
3.5.2. PBMC cells 
Peripheral blood mononuclear cells (PBMC) constitute an important part of 
human peripheral immune system. PBMC cells consist mainly of monocytes, T-
cells and B-cells, and smaller amounts of natural killer cells (NK) and dendritic 
cells of both myeloid and plasmacytoid origin. The cells are derived from 
healthy human donors and processed using the Ficoll-Hypaque method. PBMC 
cells are suitable for assessment of the general immune activation of drug 
candidates or microorganisms, for which an immune stimulation is of interest 
(e.g. vaccine adjuvants and particles, immune stimulants for cancer treatment or 
immune stimulating natural extracts or micro organisms). The PBMC cells are 
suitable in vitro model for screening the compounds for immune-modulatory 
effects. In Paper I, the PBMC cells were used as a model non-cancer system for 
immune response studies in vitro as they are also capable of IL-1 and TNF-α 
cytokine production. 
 
 
3.5.3. Breast cancer cell lines 
MCF-7 and MDA-MB-231 breast cancer cell lines used in this thesis are 
derived from tumor metastasis pleural effusions. MCF-7 is an invasive human 
ductal carcinoma and is the most common breast cancer cell line in cancer 
studies.229 MDA-MB-231, a human breast adenocarcinoma cell line, was 
isolated from the patient with MTX resistance due to the lack of MTX transport 
protein while receiving chemotherapy. Both MCF-7 and MDA-MB-231 breast 
cancer cell lines are of adenocarcinoma origin but differ in the tumor suppressor 
protein p53 expression. MCF-7 is a wild-type p53 expressing cell line, while in 
MDA-MB-231 cells the p53 protein is inactivated due to mutations and these 
aspects were utilized in Paper II to investigate the effect of p53 C-terminal 
domain-derived CPP-s Peptide4 and Peptide5 on the restoration of the p53 
functions and induction of apoptosis inside the tumor cells. 
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3.5.4. SK-N-AS cell line 
SK-N-AS is an S-type human neuroblastoma cell line derived from the bone 
marrow of an eight-year-old girl. The primary site of the tumor was found to be 
localized in adrenal glands soon metastasing however to the bone marrow. The 
SK-N-AS cell line is adapted to serum-free conditions because it is consti-
tutively expressing IGF-2. The ability of neuroblastoma cell line to grow in 
serum-free conditions in the absence of supplied growth factors has been used 
in Paper II in order to study the effect of p53-derived cell-penetrating protein 
analogues under serum withdrawal conditions. SK-N-AS cells have a deletion 
in chromosome 1p region, which is a common non-random genetic alteration 
resulting in several putative tumor suppressor genes (p53) dysfunction in many 
neuroblastoma and breast cancer cell lines. 
 
 
3.5.5. HEK 293 cell line 
The HEK 293 Human Embryonic Kidney 293 cell line was generated in the 
early 70s by adenoviral transformation of normal human embryonic kidney 
cells in Alex Van der Eb's laboratory in Leiden, The Netherlands.230 HEK 293 
cells are easy to transfect and have been widely used in cell biology research as 
well as biotechnology industry to produce therapeutic proteins and viruses for 
gene therapy. HEK 293 cell line is an experimentally transformed cell line and 
thus is not a suitable model for cancer studies. However, they are easy to handle 
and are commonly used in drug delivery and peptide uptake studies (Paper III).  
 
 
3.5.6. U87 MG cell line 
U87 is a human glioblastoma-astrocytoma cell line formally known as U87 MG 
(malignant glioma). Glioblastoma is the highest dedifferentiated form of 
astrocytic brain tumours and it is refractory to chemotherapy in most cases. U87 
cells have epithelial morphology and were obtained from a stage IV cancer 
patient. The cell line was used in Paper III as an in vitro model of human glio-
blastoma to investigate tumor targeting and the cytotoxic effect of tumor 
targeted CPP-s towards the cancer cells. 
 
 
3.5.7. HeLa cell lines 
HeLa cell line derived from immortalized cervical cancer cells isolated in 1951 
from Henrietta Lacks after her death. HeLa is one of the most widely used cell 
lines within various research fields and in particular in cancer studies. The cells 
are characterized as rapidly growing and robust. HeLa cells were used in Paper 
III as a common cancer cell line model for investigation of specific inter-
nalization mechanisms and cytotoxicity induced by novel designed CPP-s. 
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In Paper IV, the delivery efficiency of CPP/SCO complexes was evaluated 
in HeLa pLuc705 cell line, the widely used splice correction assay.233 HeLa 
pLuc705 cell line is stably transfected with luciferase-encoding gene interrupted 
by a mutated intron 2 from β-globin gene carring a cryptic splicing site. 
Incomplete removal of the intron (during splicing) results in production of 
aberrant and non-functional luciferase. Shielding the cryptic site with SCO-s 
enables to restore the splicing producing functional luciferase. This splice-
correcting assay provides a positive read-out over the low background while 
having a wide dynamic range. 
 
 
3.5.8. CHO cell line 
Chinese hamster ovary (CHO)-K1 cell line is the most commonly used cell line 
in studies of genetics, toxicity screening, and gene expression. It is a subclone 
of the parental CHO cell line, which was derived from the ovary of an adult 
Chinese hamster,231 it contains a slightly lower amount of DNA than the 
original CHO. These cells have been widely used in CPP field. CHO cells were 
used in Paper IV for plasmid delivery assay  
 
 
3.5.9. BHK 21 cell line 
Baby Hamster Kidney fibroblast (BHK 21) is an adhesive cell line used in 
molecular biology. The cells were derived in 1961 by Macpherson and 
Stoker.232 Nowadays, subclone 13, originally derived by single-cell isolation 
from the kidneys of 5 unsexed, 1-day-old hamsters, is widely used. The BHK 
21 cells are mainly useful for transformations and for stable and temporary 
transfections. BHK 21 cells were used in Paper IV for plasmid delivery assay 
 
 
3.6. Characterization of uptake of CPP-s 
There are several methods for the characterization of peptide mediated uptake 
and drug delivery efficacy inside cells. The most widely used of them is the 
labelling of either the peptide or the nucleic acid polymer with a fluoresceinyl 
moiety. In the current thesis the 5(6)-carboxyfluoresceinyl moiety was 
covalently coupled to the peptide backbone in order to quantify the uptake and 
delivery efficacy of newly designed CPP-s into human cells. 
 
 
3.6.1. Confocal microscopy 
Fluorescence microscopy and confocal laser scanning microscopy enable the 
evaluation of fluorescein-labelled CPP-s uptake inside the cell or in tissue 
sections, providing valuable information about their intracellular localization 
and targeting. Live-cell imaging was used in all microscopy studies in this 
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thesis. Live-cell imaging was preferred to fixed and permeabilized cell 
visualization in order to avoid possible fixation-derived artefacts often 
interfering with correct image analyses. In Papers II, III and IV), the 
microscopy studies of fluorescein-labelled CPP-s were performed using an 
Olympus IX81 inverted microscope equipped with a FluoView 1000 confocal 
system with 60× water-immersion and 100× oil-immersion objectives and 
excitation at 488 nm (fluorescein). Images were captured using a digital camera 
(model DXM1200C) and processed with EZ-C1 software V.2.30 (Nikon, 
Japan).  
 
3.6.2. Flow cytometry  
Flow cytometry is a powerful technique for analysis of multiple parameters of 
individual cells within a heterogeneous population. Fluorescence-activated cell 
sorting (FACS) is used in various applications such as immunophenotyping, 
chromosomal ploidy analysis, cell counting and GFP expression analysis. FACS 
performs these analyses by passing thousands of cells per second through a 
laser beam and capturing the light that emerges from each cell as it passes 
through. The data are analyzed by flow cytometry software to obtain cellular 
characteristics such as size, complexity and viability. In Papers II and III, the 
flow cytometry was used in order to estimate the cell-penetrating activity of 
newly designed fluorescein-labelled peptides providing both qualitative (FITC 
mean) and quantitative (percentage of transfected cells) analyses. 
 
 
3.7. Toxicity studies in vitro 
The translocation of the CPP-s through cellular membrane can be accompanied 
by cytotoxic side effects derived from membrane perturbation especially at high 
peptide concentrations. In this thesis several methods were used to investigate 
the effect of these peptides on short-term membrane disturbance as well as 
long-term effects on cellular proliferation.  
 
 
3.7.1. LDH leakage assay 
The LDH leakage assay is based on lactate dehydrogenase (LDH), a soluble 
cytosolic enzyme that is released into the culture medium following loss of 
membrane integrity resulting from either apoptosis or necrosis. LDH activity 
can be used as an indicator of cell membrane integrity and serves as a general 
means to assess cytotoxicity resulting from chemical compounds or environ-
mental toxic factors. In the first step, LDH catalyzes the reduction of NAD+ to 
NADH and H+ by oxidation of lactate to pyruvate. In the second step of the 
reaction, diaphorase uses the newly formed NADH and H+ to catalyze the 
reduction of a tetrazolium salt (INT) to highly coloured formazan, which 
absorbs strongly at 490–520 nm. In Paper III and IV LDH leakage assay was 
11
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performed in order to estimate the effect of the cell-penetrating vector gHoPe2 
on cellular membrane integrity before conjugation of the vector with the 
chemotherapeutic molecules. 
 
 
3.7.2. Cell proliferation assay 
For investigation of long-term effects of CPP-s and CPP/cargo complexes on 
cell proliferation and survival a tetrazolium salt-based colorimetric MTS 
proliferation assay was performed (Paper I, III and IV)). The principle of the 
assay is to detect the metabolizing cells by measuring the activity of the 
intracellular enzyme mitochondrial dehydrogenase that in the presence of 
phenazine methosulphate reduces tetrazolium to formazan dye giving a purple 
colour with absorbance maximum at 490–500 nm in phosphate-buffered saline. 
In Paper II, long-term toxicity of cell-penetrating protein analogues was 
evaluated using CellTiter-Glo® Luminescent Cell Viability Assay (Promega, 
Sweden). The CellTiter-Glo® Luminescent Cell Viability Assay is a similar 
method to determine the number of viable cells in culture based on quanti-
fication of the ATP, which signals the presence of metabolically active cells. 
Luminescent Cell Viability Assay results in cell lysis and generation of a 
luminescent signal proportional to the amount of ATP present. The amount of 
ATP is directly proportional to the number of cells in culture. 
 
3.8. ELISA assay 
Enzyme-linked immunosorbent assay (ELISA) is a plate-based immunoassay 
for detection and quantification of substances such as peptides, proteins, 
antibodies and hormones. The main principle of the assay is the immobilization 
of the antigen of interest that can be accomplished by direct adsorption to the 
assay plate or indirectly via a capture antibody that has been attached to the 
plate. The antigen is detected either directly (labelled primary antibody) or 
indirectly (labelled secondary antibody). The most powerful ELISA assay 
format is the sandwich assay where the antigen is bound between two primary 
antibodies-the capture antibody and the detection antibody. The sandwich 
format has high selectivity and sensitivity as the key element of the detection 
strategy is a highly specific antibody-antigen interaction. In Paper I, the ELISA 
assay was used in order to analyze the influence of novel CPP-s PF-s and 
peptide/nucleic acid complexes on innate immune response by measuring IL-
1, IL-18 and TNF-α cytokine release in cell culture supernatants and mouse 
serum. 
 
3.9. Apoptosis detection assays 
Apoptosis is the best-characterized type of programmed cell death. Because of 
its importance in development, homeostasis and pathogenesis of cancer, 
apoptosis has undergone extensive investigation over the past few decades. 
43 
Several changes affecting the plasma membrane, mitochondria, cytoplasm and 
nucleus during apoptosis have been measured and analyzed. One of the earliest 
events in apoptosis is the translocation of phosphatidylserine (PS) from the 
inner to the outer leaflet of the plasma membrane that can be detected with 
annexin V. Mitochondrial dysfunction also occurs early in apoptosis and is 
accompanied by a decreased membrane potential and the release of 
mitochondrial proteins such as Cyt C and Smac/DIABLO. This leads to the 
activation of caspases-3 and 7 and DNA fragmentation.  
 
 
3.9.1. Annexin V assay 
The annexin V assay is a rapid and convenient method for detection of 
apoptosis based on flow cytometry. The human anticoagulant, annexin V, is a 
35–36 kDa Ca2+-dependent phospholipid-binding protein that has a high affinity 
for phosphatidyl serine (PS). PS is normally located on the inner cytoplasmic 
surface of the cell membrane, while during apoptosis it is translocated to the 
outer leaflet of the membrane exposing itself to the extracellular environment. 
Annexin V is labelled with a fluorophore that can identify apoptotic cells by 
binding to PS exposed on the outer leaflet. After staining a cell population with 
annexin V in the provided binding buffer, apoptotic cells show green 
fluorescence that can easily be distinguished using a flow cytometer with the 
488 nm line of an argon-ion laser for excitation. An Alexa Fluor® 488 annexin 
V assay was performed in Paper II in order to characterize the apoptotic activity 
of the newly designed p53-derived cell-penetrating protein analogues (Peptide4 
and Peptide5) in breast cancer cell lines.  
 
3.9.2. Caspase activity assay 
Caspases, essential proteins in cells for apoptosis and inflammation, were first 
implicated when Caenorhabditis elegans protein CED-3 was found to have 
close homology with the mammalian interleukin-1-converting enzyme (ICE or 
caspase 1) which when over-expressed induces apoptosis. Caspases are cysteine 
proteases, which use a cysteine residue to cleave their substrate proteins at the 
aspartic acid residue. The generic name for all members is caspase with the “c” 
denoting a cysteine protease and “aspase” referring to the aspartate specific 
cleaving ability of these enzymes. The individual members are then numbered 
according to their chronological order of publication. Currently 14 caspases 
have been identified: 12 human and 2 murine. In Paper I, PF peptide`s possible 
apoptotic and immunogenic effects were analyzed by measuring caspase-1 and 
caspase 3/7 activities in vitro. Caspase-specific peptide conjugated to fluore-
scent reporter molecule (AFC) was used as a cleavage substrate for caspase-1 
and caspase 3/7. The cleavage of this caspase-specific peptide by the caspases 
releases the fluorochrome that, when excited by light at 400 nm wavelength, 
emits fluorescence at 505 nm. The level of caspase enzymatic activity in the cell 
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lysate is directly proportional to the fluorescence signal detected with a 
fluorimeter or a fluorescent microplate reader. 
 
 
3.10. In vivo studies 
In Paper III, subcutaneous and intracranial glioblastoma xenograft bearing mice 
were utilized for in vivo studies. 
 
 
3.10.1. U87 MG tumor bearing mice 
In Paper III, homozygous female nude mice (C.Cg/AnNTac-Foxn1nu, Taconic), 
bearing tumor xenografts either intracranially or subcutaneously were 
established in order to evaluate the localization of the fluorescein-labelled 
peptide vectors. 8×105 U87 cells were resuspended in 100 μl (subcutaneous 
tumor model) or in 5 μl (intracranial tumor model) of fresh DMEM medium, 
without serum and antibiotics. The xenografting was performed by implanting 
the cell suspension subcutaneously or intracranially into the striatum. 
 
 
3.10.2. Biodistribution and tumor reduction studies 
In Paper III, biodistribution of gHoPe2 in U87 mouse xenografts was analyzed. 
At 3 h post-injection of carboxyfluorescein labelled peptide (4 mg/kg), the 
tissues were collected, fixed for 2 h in the fixation solution, cryoprotected in 
sucrose and snap frozen in 2-methylbutane (AppliChem) kept on dry ice. The 
tissues were cut on a cryostat with a thickness of 10–15 μm, counterstained with 
DAPI (AppliChem) and mounted using Vectashield (Vector Labs) mounting 
medium. The tumor treatments were performed using 1 mg/kg doxorubicin 
(369 M, 100 l, for an animal of 20 g) and an equivalent dose (8.3 mg/kg) of 
dox-gHoPe2 (369 M, 100 l) i.v. 2 times per week. The subcutaneous tumor 
dimensions were measured using caliper; tumor volume was calculated as 
(length × width2)/2.  
 
 
3.10.3. Toxicity analysis in vivo 
In Paper I, possible toxic and immunogenic effects of PF peptides were 
analyzed. The peptides were administered to immunocompetent C57BL/6 male 
and female mice via i.v. injection followed by collection of the blood samples. 
Cytokine levels in serum were analyzed at 24 and 48 h after i.v. injection of 1 
and 5 mg/kg of TAT (48–60) and their equimolar doses of 0.01 and 0.06 μmol 
per animal of TP10, stearyl-(RxR)4, PF3, PF4, and PF6 respectively. Some 
animals received LPS (10 μg i.p.). Blood samples were collected via heart 
puncture and serum was separated using serum gel-separation tubes (Terumo). 
Ketamine (75 mg/kg (Vetoquinol, Bioketan)) and dexmedetomidine (1.0 mg/kg 
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(Laboratorios SYVA S.A.U., Dorbene)) in saline solution were applied via i.p 
injection and used for anaesthesia. Liver, kidney, lung and spleen were 
dissected immediately after blood samples collection and rapidly frozen in 2-
methylbutan at –60ºC. Cryosections were fixed in formalin, stained with 
hematoxylin and eosin and used for histopathological analysis. Two mice were 
used per group in three independent experiments. 
12
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4. RESULTS AND DISCUSSION 
 
The articles included in this thesis describe the cytotoxic and immunogenic 
activity of PF CPP-s (Paper I); analyze the apoptotic activity of newly designed 
cell-penetrating p53 analogues (Paper II) and evaluate the tumor targeting and 
antitumor activity of the tumor-specific peptide-based drug delivery vector 
gHoPe2 (Paper III); estimate the nucleic acids delivery efficacy of N-terminally 
stearylated (RxR)4 and Arg9 CPP-s in vitro (Paper IV).  
 
 
4.1. Immunogenic and cytotoxic characteristicts of PF-s 
peptides (Paper I) 
CPP-s have been successfully used for the delivery of different payloads in vitro 
and in vivo. However, undesired side effects such as cytotoxicity and the ability 
to induce innate immune response, limit their application as drug delivery 
vehicles.  
In Paper I, we evaluated the influence of PF peptides and PF/nucleic acid 
complexes on the immune activity in vitro and in vivo. During the analyses the 
PF/plasmid and PF/siRNA complexes with the highest charge and molar ratios, 
that indicated to be stable in serum and showed the best transfection effective-
ness in different cell lines, received the greatest attention. The cytotoxic and 
immunologyc response of PF3, PF4 and PF6 peptides was analyzed in 
monocytic leukaemia (THP-1) and peripheral blood mononuclear cells 
(PBMC). Well-established CPP-s such as transportan 10 (TP10), TAT (48–60), 
stearyl-(RxR)4 peptides and the most widely used transfection reagents 
Lipofectamine™ 2000 and Lipofectamine™ RNAiMAX were analyzed in order 
to provide a comparison with PF in the study. Aiming to analyze the immuno-
genic activity of the peptides and peptide/nucleic acid complexes, the release of 
cytokines IL-1, IL-18 and TNF-α in cell culture medium and in mouse serum 
was detected using highly sensitive enzyme-linked immunosorbent assay 
(ELISA). For the estimation of possible toxic effects of PF3, PF4 and PF6 
peptides and their complexes with nucleic acids, the viability of THP-1 cells 
was assessed using MTS viability assay. The viability of the cells correlates 
with the activity of intracellular enzymes and their ability to reduce water-
soluble tetrazolium salts to formazan dyes. In order to estimate possible 
apoptotic effects of the PF peptides in THP-1 cells, total cellular caspase-1 and 
caspase-3/7 activity was analyzed. As a result, PF peptides as well as 
peptide/nucleic acid complexes were found to be non-toxic (non-apoptotic) and 
non-immunogenic in vitro at the peptides concentrations of 10 μM and 5 μM, 
respectively and at peptide/nucleic acid complexes charge ratios 1 and 5 (0.5 μg 
plasmid DNA) and molar ratio 40 (50 nM siRNA). PF peptides and peptide/ 
nucleic acid complexes also showed minimal influence on host immune system 
at a peptide dose of 5 mg/kg in vivo.  
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CPP-s contain fewer than 30 amino acids234 and are expected to have no 
indications for oncogene activation.214 Nevertheless, biological side effects of 
cationic and amphipathic cell-penetrating peptides has been thoroughly studied. 
The results of several studies suggest that amphipathic peptides, such as 
transportans, which have polar and non-polar portions in their structures, affect 
the normal metabolism of the cells inducing toxicity already at a concentration 
of 5 M.142, 235 Design of PF peptides is based on the TP10 sequence with 
incorporated stearyl and/or trifluoromethylquinoline (chloroquine) groups. 
Chloroquine possesses immunosuppressive activity and has been utilized for the 
treatment of autoimmune disorders.236 Recently, chloroquine was found to 
enhance the endosomal release of peptide-based delivery vectors providing 
higher intracellular activity of delivered cargos. Nevertheless, chloroquine has 
been associated with several toxicity cases, including retinal injury and skin 
irritations particularly when provided at high doses for a long duration.237, 238 
These data indicate the possibility that transportan derived PF peptides may 
trigger the undesired toxic or inflammatory effects. We investigated possible 
toxic and immunogenic activity of the PF peptides and compared it with activity 
of the widely used cationic CPP-s such as TAT (48–60), stearyl-(RxR)4 and 
amphipathic TP10. The results of our study did not show any cytotoxic and 
immunogenic activity of PF peptides in vitro and these effects were similar with 
TP10, and also with TAT (48–60) and stearyl-(RxR)4 peptides. In vivo, 
systemically administered, PF peptides did not induce inflammation or histo-
pathological changes in liver, kidney, lung and spleen of the immunocompetent 
mice, even at the peptide much higher than the doses used for in vivo nucleic 
acid delivery.239 We concluded that the peptides have no influence on the 
inflammatory response suggesting that introduced stearyl and chloroquine 
groups do not interfere with cellular viability and immunogenicity.  
Although the novel TP10 analogues used in this study were found to be non-
toxic and non-immunogenic in vitro and in vivo long-term toxicity and immuno-
genicity studies are needed to confirm the data. In conclusion, our studies 
demonstrate that PF peptides are efficient non-toxic and non-immunogenic 
peptide-based vectors for nucleic acid delivery both in vitro and in vivo, 
showing potential for their future therapeutic application without risk of inflam-
mation. 
 
 
4.2. Induction of apoptosis by p53-derived CPP-s  
(Paper II) 
Cell cycle arrest, DNA repair, and apoptosis are the most common responses to 
DNA damage in normal mammalian cells. Genetic instability and malignant 
transformation are consequences of improper DNA damage responses.240–242 
Tumor suppressor proteins play an important role in the regulation of tissue 
homeostasis and in the prevention of the genetically damaged cell proliferation.  
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It has been previously shown that the lysine-rich domain of the C-terminus of 
p53 is able to induce apoptosis by activating wild-type p53 protein and restoring 
its normal functions in cancer cells.213, 215 In Paper II, we developed novel 
human p53 C-terminal domain-derived stearyl-modified peptides (Peptide4 and 
Peptide5), which showed specific apoptotic activity in breast cancer cell line 
where the p53 activity is suppressed. Applying the CPP prediction algorithm the 
p53 protein-derived CPP-s were designed and synthesized by standard Fmoc 
chemistry. Peptide4 and Peptide5 peptide sequences were derived from the 
primary amino acid sequence of p53 available from the NCBI Human Protein 
Database. In order to investigate the cell-penetrating properties of newly 
designed p53-derived analogues the peptides were labelled with carbo-
xyfluorescein and the uptake was analyzed in SK-N-AS cells using confocal 
microscopy. Detection of a green fluorescent signal inside the cells confirmed 
the intracellular translocation of the p53-derived peptides. The introduction of a 
stearyl group in the structure of CPP-s was used to overcome the problem of 
endosomal entrapment of drug delivery agents (Paper IV).59, 222, 243 As it was 
shown in Paper I and IV, the incorporation of the stearyl group in the peptide 
sequence does not induce the non-specific toxicity and immunogenicity and will 
provide no interference with the apoptotic activity of the novel peptides.244 The 
orthogonal addition of the stearic acid moiety via lysine 3 improved the 
intracellular penetration activity of the peptides. The quantitative uptake of the 
stearylated Peptide4 and Peptide5 in breast cancer cell lines MDA-MB-231 and 
MCF-7 was estimated using flow cytometry (FACS). The results from FACS 
analyses showed higher cellular uptake of the stearylated peptides compared to 
unmodified peptides. The effect was observed in both cell lines, especially 
under the condition of foetal bovine serum withdrawal. The penetration ability 
of Peptide4 and Peptide5 was strongly influenced by the presence of foetal 
bovine serum in the incubation medium: up to 10-fold higher uptake of 
stearylated peptides was estimated in both MDA-MB-231 and MCF-7 cell lines 
in serum free medium. On the other hand, unmodified peptides showed only 
minor cell-penetrating activity in serum free and complete media in both breast 
cancer cell lines. 
The Peptide4 and Peptide5 were also found to be capable of specific 
induction of cytotoxic and apoptotic effects in p53-non-active breast cancer cell 
lines in the absence of serum. The ability of the Peptide4 and Peptide5 to induce 
cytotoxicity and apoptosis was analyzed in p53-non-active and p53-intact breast 
cancer cell lines. Long-term toxicity measurements were performed using 
Luminescent Cell Viability Assay and apoptotic effects in breast cancer cells 
were analyzed using an annexin V apoptosis kit. Despite intracellular trans-
location, Peptide4 and Peptide5 showed no cytotoxic effect in MDA-MB-231 
cell line after 24 h of incubation. The peptides remained non-toxic even at a 
concentration of 40 M, which is the highest concentration used in this study. In 
contrast, MCF-7 cells showed mild reduction in viability already after 24 h of 
incubation with the peptides, but this result was not confirmed by the further 
apoptotic analyses. Prolonged incubation (48 h) with Peptide4 and Peptide5  
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(20 M) specifically reduced the viability of the cells up to 60 %. The induction 
of apoptosis in MDA-MB-231 cells, however, was observed already after 24 h 
of incubation under serum free conditions: 67 % of the MDA-MB-231 popu-
lation had exhibited early apoptotic activity. At the same time Peptide4 and 
Peptide5 did not influence the viability of wild-type p53 bearing MCF-7 cells 
even after 48 h of incubation under similar conditions. It is important to note 
that Peptide4 and Peptide5 peptides failed to induce apoptosis in MDA-MB-231 
cells when incubated with the cells in the presence of serum. The reduced 
activity of Peptide4 and Peptide5 can be explained by the enhanced degradation 
of the p53 inside the cancer cells.215, 245, 246 Therefore, higher concentrations of 
the peptides might be needed to obtain the significant effect in vitro. The 
obtained data also suggest that further in vivo studies are required in order to 
investigate the influence of blood serum on the p53-derived CPP-s activity. 
Additionally, the anti-tumor properties of the Peptide4 and Peptide5 can be 
enhanced by the conjugation of the peptides to the pro-apoptotic agents 
achieving thereby the synergistic effect on tumor cell viability.  
In summary, our study demonstrated that Peptide4 and Peptide5, the peptide 
sequences of which were generated by using QSAR-based algorithm, are prone 
to penetrate inside the cells inducing specifically apoptosis in p53- non-active 
breast cancer cell line. The introduction of stearic acid moiety in the Peptide4 
and Peptide5 backbone at N-terminal or lysine 3-orthogonal positions similarly 
enhanced the cellular uptake of these peptides, improving their cytotoxic and 
apoptotic activities in a serum free environment. Being capable of cellular 
translocation and having an apoptosis inducing effect, Peptide4 and Peptide5 
might be implemented together with various cytotoxic agents for anticancer 
treatment. These findings suggest that novel p53-derived CPP-s have a 
promising potential in the anticancer therapy. 
 
 
4.3. Development of the glioma-targeted drug delivery 
vector gHoPe2 (Paper III) 
Cancer is the leading cause of death in economically developed and developing 
countries.247–249 In particular the treatment of gliomas is therapeutically chal-
lenging with drug delivery being limited due to either insufficient penetration 
through the blood-brain barrier or the overly fast clearance.250  
Paper III describe the development of the tumor-targeted delivery vector 
gHoPe2 based on a glioma-targeted peptide sequence gHo, which was identified 
by using in vitro phage display technology.113  
The main aim of the study was to create an efficient drug delivery vector 
capable of penetration through the blood-brain barrier and selective targeting of 
the tumor tissue/cells. The novel glioma-targeted delivery vector was generated 
by a covalent conjugation of well-established CPP pVEC and glioma-targeted 
sequence gHo. The incorporation of gHoPe2 into a widely used chemo-
therapeutic drug doxorubicin resulted in the formation of the conjugate dox-
13
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gHoPe2. The gHo sequence tumor targeting properties were verified by 
analysing the binding activity of the carboxyfluorescein (FAM) labelled gHo 
sequence to the membrane of malignant glioblastoma cells (U87 MG) using 
confocal microscopy. The detection of green fluorescence signal on the 
membrane of the U87 MG cells but not the HeLa and HEK 293 cells after 
incubation even with high concentrations (10 and 20 μM) of the peptide 
confirmed specific association of the gHo with glioblastoma. 
In order to evaluate the cellular uptake of glioma-targeted delivery vector 
gHoPe2, the peptide was labelled with carboxyfluorescein and assessed 
qualitatively using confocal microscopy and quantitatively using flow 
cytometry. gHoPe2 showed high cellular uptake inside the U87 MG cells, while 
gHo sequence not conjugated to CPP did not internalize into the cells. The 
characterization of the gHoPe2 proceeded in in vivo studies, where the 
biodistribution of FAM-labelled gHoPe2 was determined. Precise examination 
of different tissues confirmed specific localization of gHoPe2 in the tumor. The 
gHoPe2 was internalized into the intracranial tumor but not into intact brain, 
kidney and liver. At the same time the non-conjugated pVEC and gHo were not 
detected in any of the examined organs.  
Thereafter the treatment efficacy of novel glioma-targeted delivery vector 
was assessed. The gHoPe2 was conjugated to chemotherapeutic drug doxo-
rubicin and the cytotoxic effect of free doxorubicin and doxorubicin assembled 
into delivery vector dox-gHoPe2 was validated. Both free and complexed 
doxorubicin reached the cell interior. The ability of dox-gHoPe2 to reduce the 
viability of the glioblastoma cells in vitro was examined. As a result dox-
gHoPe2 exhibited similar cytotoxic efficiency as free doxorubicin. Although 
doxorubicin is one of the most potent chemotherapeutic drugs and has shown a 
high antitumor effect in vitro, its activity against brain tumor in vivo remains 
quite low.  
In order to investigate if dox-gHoPe2 would have an advantage over free 
doxorubicin in vivo the efficacy of both compounds was analyzed in the models 
of subcutaneous and intracranial gliomas. The dox-gHoPe2 and free doxo-
rubicin were administrated via i.v injection two times per week within 17 days 
of the experiment. Subcutaneous U87 tumor growth was monitored by 
recording tumor size 2 times per week. Tumor growth dynamics revealed a 
significant effect of the treatment with dox-gHoPe2 as the tumors in this group 
were smaller then the tumors in the untreated group. Also the body weight loss 
of the intracranial glioma bearing mice was less in the group that received dox-
gHoPe2 compared to the free doxorubicin-receiving group although the 
observed effect was statistically not significant. Unfortunately, the admi-
nistration of both dox-gHoPe2 and free doxorubicin did not prolong the survival 
of the animals probably because the dose of 1 mg/kg used in this study was too 
low to induce the reduction of tumor volume. Yet the inhibition of tumor 
growth was observed only in subcutaneous tumors suggesting that higher 
amount of dox-gHoPe2 is required to achieve tumor regression and an effect on 
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survival in intracranial tumor model. Therefore, more experiments are needed in 
order to verify the effect of the dox-gHoPe2 vector in vivo.  
There are not many reports demonstrating the development of a vector 
system for the effective systemic treatment of gliomas. Recently, Ruoslahti et 
al., have developed a glioblastoma-targeting tumor-penetrating peptide-based 
nanosystem that increased the survival of glioblastoma 005251 xenografts from 
32 to 52 days. However, the extended treatment did not provide further survival 
of the animals.252 These data confirm that the treatment of glioblastoma is likely 
a very challenging process. Our study demonstrates for the first time the 
applicability of the combined approaches for tumor treatment, utilizing the in 
vitro phage display for the detection of novel peptide sequences capable of 
selective binding to certain tissues or cell types and CPP-s to provide the 
intracellular delivery of the cytotoxic drugs. Effective and specific localization 
of the vector to the glioma demonstrated in this study confirmed the successful 
application of the in vitro phage display for tumor targeting. Nevertheless the 
additional experiments are still needed to improve the activity of the novel 
tumor-targeted drug delivery vector.  
In summary, Paper III demonstrates the potential application of CPP-s for 
the treatment of the invasive tumors. The strategy successfully combines the in 
vitro phage display for the detection of novel tumor-selective peptide sequences 
and the conjugation of these sequences to the CPP-s in order to develop highly 
efficient tumor-targeted drug delivery system.  
 
 
4.4. Nucleic acids delivery with  
stearyl-(RxR)4 peptide by non-covalent co-incubation 
strategy (Paper IV) 
The (RxR)4 peptide has been utilized for the delivery of covalently conjugated 
splice-correcting oligonucleotides (SCO) and phosphorodiamidate morpholino 
oligonucleotides (PMO),253, 254 and has been already applied in pre-clinical 
trials.255 The aim of this study was to modify (RxR)4 peptide with stearic acid 
moiety and to utilize it for SCO-s and plasmid DNA delivery using non-
covalent conjugation strategy. 
The size of the nanoparticles of stearyl-(RxR)4/pDNA complexes was 
around 370–450 nm depending on charge ratio 1:5 and 1:3, respectively. The 
nanoparticles were capable to mediate efficient intracellular delivery of pGL3 
luciferase expressing plasmid. The plasmid delivery experiments were per-
formed in CHO, BHK 21 and HEK 293 cell lines. The obtained data were 
compared with the data observed by using stearyl-Arg9, which has been showen 
to be able to transport plasmids into the cell.256 Although stearyl-Arg9 de-
monstrated some capacity for intracellular plasmid delivery, it was less efficient 
compared to stearyl-(RXR)4 and Lipofectamine™ 2000 transfection agent, 
which was used as a positive control in this experiments. Although the trans-
fection efficacy of Lipofectamine™ 2000 was significantly higher compared to 
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stearyl-(RxR)4, also high cytotoxic effect of Lipofectamine™ 2000 was ob-
served: the viability of the cells was reduced more than 30 % as compared to 
untreated cells.257 At the same time stearyl-(RxR)4 did not show any toxicity in 
similar transfection conditions. To assess cellular uptake of stearyl-(RxR)4/ 
plasmid complexes, CHO cells were transfected with EGFP expressing plasmid 
and analyzed by confocal microscopy. Stearyl-(RxR)4/plasmid complexes as 
well as stearyl-(RxR)4/SCO-s complexes transfected uniformly most of the cell 
population. Lipofectamine™ 2000/pDNA complexes failed to transfect the 
entire cell population. 
The (RxR)4 peptide conjugated to SCO-s has been successfully utilized in 
vitro and in vivo.258–260 However, using a non-covalent co-incubation strategy, 
the peptide was not able to mediate any splice correction in HeLa pLuc705 
cells.233 In this study we analyzed the ability of stearyl-(RxR)4 to deliver SCO-s 
into the cells using non-covalent approach. As a result stearyl-(RxR)4 promoted 
efficient splice correction. Splice correction efficiency as high as 20-fold was 
observed at SCO-s concentration of 200 nM at molar ratio 3. The SCO con-
centrations needed to obtain efficient splice correction with stearyl-
(RxR)4/SCO-s complexes were much lower compared to the concentrations 
necessary when utilizing the covalent conjugation strategy of (RxR)4-PMO, 
which are in μM concentration range.254 
The hydrophobicity might also play an important role in the CPP-s mediated 
plasmid and oligonucleotide delivery. Introduction of a hydrophobic stearyl 
moiety to the (RxR)4 structure significantly increased both pDNA and SCO-s 
delivery, while the same modification of Arg9 has significantly lower effect. 
Stearyl-(RxR)4 showed to be an effective nucleic acid delivery vector, although 
its transfection efficiency did not reach levels of Lipofectamine™ 2000. At the 
same time stearylation of Arg9 did not have any effect on the nucleic acid 
delivery, indicating that the successful implementation of stearylation is 
dependent on the properties of the used CPP. It has been showen that 
stearylation of TP10 had higher effect on oligonucleotides delivery,222 than 
stearylation of (RxR)4. This can be explained by the amphipathic/hydrophobic 
origin of TP10. (RxR)4 and stearyl-(RxR)4 complexed with Cy5-labelled SCO-s 
were taken up in comparable quantities suggesting that small differences in 
uptake could not account for the large differences in biological activity, 
indicating the central role of the stearic acid moiety. Moreover, we can assume 
that these complexes were taken up by endosomal pathway, indicating that 
stearic acid promotes endosomal escape of stearyl-(RxR)4 peptide.  
In conclusion, stearyl-(RxR)4 enables efficient pDNA and SCO-s delivery in 
non-toxic manner using non-covalent co-incubation strategy. Moreover, dose-
dependent splice correction provided by non-covalent approach was comparable 
with (RxR)4-PMO covalent conjugation, but using at least 10-times lower 
peptides concentration. These properties of stearic acid modified (RxR)4 in 
combination with the simplicity of experimental set-up make it a promising 
delivery vector for future in vivo application. 
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5. CONCLUSIONS 
 
The findings of this thesis provide information about the cytotoxic and immuno-
genic activity of TP10-derived CPP-s PF3, PF4, PF6, the apoptotic activity of 
p53-derived short synthetic CPP-s Peptide4, Peptide5, tumor-targeted delivery 
by novel gHoPe2 drug delivery vector and transfection efficacy of stearylated 
CPP (RxR)4. The main conclusions of the Papers I, II, III and IV included in the 
thesis are the following: 
 
Paper I 
The analysis of cytotoxic and immunogenic activity of PF3, PF4 and PF6 
peptides in THP-1 cells, peripheral blood mononuclear cells and in mice serum 
showed no cytotoxic and immunogenic effect for the examined peptides in vitro 
at concentrations of 10 μM and 5 μM respectively and at dose of 5 mg/kg in 
vivo. The current study confirms that PF3, PF4 and PF6 peptides have a pro-
mising potential in plasmid and siRNA delivery with no evidence of undesired 
toxicity and inflammation. 
 
Paper II 
Novel human p53-derived Peptide4 and Peptide5 are capable of translocation 
inside the neuroblastoma and breast cancer cell lines. Moreover these peptides 
exhibit specific apoptotic activity towards the p53-non-active MDA-MB-231, 
but not the MCF-7 cells, where p53 is intact. The observed apoptotic effect was 
more pronounced under the condition of serum withdrawal in vitro. Novel p53-
derived CPP-s Peptide4 and Peptide5 may have a promising role in future 
anticancer strategy. 
 
Paper III 
The gHoPe2 vector demonstrated effective and specific localization to the 
glioma in vivo. The chemotherapeutic drug conjugated to the gHoPe2 vector 
proved to be efficient in vitro and in vivo. Development of the delivery vectors 
based on the conjugation of targeting moiety and CPP-s is a promising strategy 
for future antitumor applications. 
 
Paper IV 
The stearylation of N-terminus of (RxR)4 significantly increases plasmid DNA 
and oligonucleotides delivery showing no cytotoxicity in vitro. Stearyl-(RxR)4 
was significantly more efficient than non-modified (RxR)4 and stearyl-Arg9, but 
not as effective as lipofectamine transfection reagent. The splice correction 
effect of stearyl-(RxR)4, using non-covalent co-incubation strategy was 
comparable to that of the pre-clinically used (RxR)4-PMO. The versatility of the 
stearyl-(RxR)4 in combination with its non-toxic properties makes it a pro-
mising vector for further in vivo applications. 
14
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SUMMARY IN ESTONIAN 
 
Rakku sisenevad peptiidid:  
tsütotoksilisus, immunogeensus ning rakendamine  
tuumor-spetsiifilise transportvektorina 
 
Terapeutilise toimega ravimite kasutamine kasvajate ravis on takistatud peami-
selt nende ebaefektiivse ja mitteselektiivse toime tõttu süsteemsel organismi 
viimisel. Uued strateegiad, mis tõhustaksid ravimi manustamise efektiivsust 
ning sisseviimise spetsiifilisust, on seega väga vajalikud. Viimastel aastatel on 
suur tähelepanu pööratud mitmesugustele ravimainete sisestamise mehhanis-
midele, mis ühendavad endas nii ravimite spetsiifilise kui ka vähivastase 
kemoteraapia strateegiaid.95 Võttes arvesse neid aspekte on rakku sisenevad 
peptiidid (RSPd või CPP-s, cell-penetrating peptides) osutunud väga tõhusateks 
vektoriteks terapeutiliste ravimite sisseviimisel. RSPde kaudu on võimalik nii 
rakukultuuri kui ka elusasse organismi transportida erinevaid bioloogiliselt 
aktiivseid aineid nagu proteiine ning nukleiinhappeid (plasmiidne DNA 
(pDNA) ja splaissingut korrigeerivaid oligonukleotiide (SKO)). Muude (näiteks 
viiruslike) vektorite kasutamine on piiratud nende poolt põhjustatud kõrval-
toimete tõttu: tsütotoksilised efektid ning immunvastuse esilekutsumine. 
Käesoleva töö peamiseks eesmärgiks oli analüüsida uute RSPde, PepFect-ide 
immunoloogilist ja tsütotoskilist aktiivsust in vitro ja in vivo; uurida p53 
analoogsete peptiidide tsütotoksilisust ning apoptootilist toimet rinnavähi raku-
mudelil ning välja töötada uus RSP, mis on võimeline sisenema ja spetsiifiliselt 
ära tundma peaajuvähi rakke gliobalstoomi (U87 MG) rakumudelil nii in vitro 
kui ka in vivo. 
Esimeses töös näidati, et uued RSPd PepFect-id, mis põhinevad peptiidi 
transportaan järjestusel, ei avaldanud tsütotoksilist ega immunogeenset toimet 
immuunsüsteemi rakkudele peptiidi kontsentratsioonidel 5 µM ja 10 µM in 
vitro tingimustes. Sarnane tulemus saadi ka immunokompetentsete hiirte süsti-
misel, kui kasutatud annused olid suuremad kui 5 mg/kg kohta.  
Teises töös disainiti ning sünteesiti lühikesi p53-analoogseid peptiide, mis 
lisaks efektiivsele rakku sisenemisele avaldasid ka apoptootilist toimet rinna-
vähi rakkudele in vitro (seerumivabas keskkonnas). Lühikesed p53-analoogsed 
peptiidid omavad head perspektiivi vähivastase strateegia arendamiseks. 
Kolmandas töös kirjeldati uue transportvektori, gHoPe2, väljatöötamist, mis 
on võimeline spetsiifiliselt sihtmärkrakkudesse sisenema. Demonstreeriti ka 
selle potentsiaalseid kasutusvõimalusi ning toimet ainete transpordil vähirakku-
desse. 
Neljandas töös näidati, et mitteamfipaatse ja sünteetilise (RxR)4 peptiidi 
stearüülhappega N-terminaalse modifitseerimine tagab efektiivse ning mitte 
toksilise nukleiinhappete transporti rakkudesse. 
Käesolev töö annab täiendava ülevaate vähispetsiifilistel RSPdel põhineva-
test transportsüsteemidest, hinnates nende toksilisust, immunogeenset aktiivsust 
ning spetsiifilist transporti kasvajarakkudesse. 
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